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A R T I C L E
Th e advent of serotherapy in Britain 




Th e introduction of antitoxins and the growth of sero-
therapy in Britain can be tracked by analysing succes-
sive editions of Th e Extra Pharmacopoeia of Martindale 
and Westcott. Th is study shows how the nature, dosing, 
use, benefi ts and side-eff ects of the principal products 
evolved between 1895 and 1920. No new serum prod-
ucts appeared after 1906, when novel therapeutic vac-
cines started to become popular, although the two 
types of preparation co-existed and were sometimes 
used in combination. Antitoxins and serums for both 
therapy and prophylaxis received a further boost be-
cause of the medical needs of the First World War.
Introduction
In the late nineteenth century, developments in micro-
biology and bacteriology led by Louis Pasteur (1822-
1895) in France and Robert Koch (1843-1910) in Ger-
many brought a new understanding of the agents 
causing infectious diseases and new ways to tackle 
them. Animals could be protected from a virulent path-
ogen by inoculating them with an attenuated version, 
though not without risk of causing infection.
On 6 December 1890 Th e Lancet and the British 
Medical Journal reported work published two days ear-
lier in the German Medical Weekly: at Koch’s renowned 
Institute of Hygiene in Berlin, Emil Behring (1854-
1917) and Shibasaburo Kitasato (1852-1931) had suc-
ceeded in curing animals infected with diphtheria or 
tetanus bacilli, and in rendering animals immune to 
these diseases.1, 2
In each case, the key to this immunity was a spe-
cifi c property of blood serum that made harmless the 
lethal toxin produced by each bacillus. A detailed sum-
mary published one week later made clear that this im-
munity could be readily transmitted from one animal 
to another by transferring serum. Importantly, the ‘an-
titoxins’ made by inoculating animals with either diph-
theria or tetanus toxin were potentially useful for both 
the cure and prevention of their respective diseases in 
humans.3
Th is paper examines the introduction of antitoxins 
and the subsequent expansion of serotherapy in Britain 
as refl ected in Th e Extra Pharmacopoeia of Martindale 
and Westcott.
Th e Extra Pharmacopoeia
Successive editions of pharmacopoeias refl ect scientifi c 
and medical advances, the arrival of new remedies, 
changes in medical practice, improved analytical tech-
niques and introduction of quality standards. Th e Brit-
ish Pharmacopoeia was fi rst published in 1864, but sub-
sequent editions and occasional addenda were published 
infrequently, making it unsuitable to track fast-chang-
ing developments, especially around the turn of the 
century.4
Another resource is the British Pharmaceutical Co-
dex, published by the Pharmaceutical Society of Great 
Britain, which included preparations that were offi  cial 
in the pharmacopoeias of France, Germany and the 
United States, although the fi rst edition came out only 
in 1907. An alternative is one of the compendiums that 
included non-offi  cial preparations – designed to supple-
ment the offi  cial pharmacopoeia – and were regularly 
updated.5
Most useful for tracking the timetable of serother-
apy is Th e Extra Pharmacopoeia of Unoffi  cial Drugs and 
Chemical and Pharmaceutical Preparations, originally 
issued in 1883.6 Its founder was William Martindale 
(1840-1902), who owned the London pharmacy busi-
ness trading as W. Martindale of New Cavendish 
Street, and who was president of the Pharmaceutical 
Society of Great Britain in 1899-1900. He and subse-
quently his son, Dr William Harrison Martindale 
(1874-1933), worked together with Dr William Wynn 
Westcott (1848-1925), a London coroner, to produce 
new editions of what became Th e Extra Pharmacopoeia 
of Martindale and Westcott at intervals of three years or 
less until 1915, and every four or fi ve years thereafter.7, 8
Th e Extra Pharmacopoeia contains references to con-
temporary medical and chemical papers in journals and 
periodicals, which mainly concern therapeutic use, pro-
vided for the benefi t of ‘the prescribing physician and 
the general practitioner’. Th e authors quote from the 
latest versions of offi  cial pharmacopoeias from the 
United States and Europe, the pharmacopoeias of the 
London hospitals, and specialist monographs. Last, but 
not least, they draw on the authority of independent 
institutions such as the British Institute of Preventive 
Medicine (BIPM).9
Each of the ten editions of Th e Extra Pharmacopoe-
ia from 1895 to 1920 carried a special chapter on anti-
toxins and serums, which allows the introduction of 
new serum products into Britain and their further evo-
lution to be tracked over time.10-19 Th e advantage of us-
ing this publication is the frequency and regularity with 
which the editions were updated, the consistency of au-
thorship and approach, and the wide range of local and 
international sources drawn upon. Th is series thus re-
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cords the variety of new antitoxins and serums, chang-
es in their preparation and use, important scientifi c de-
velopments, and the evolution of terminology.
Reliance on a single publication has limitations 
since its content inevitably refl ects the choice of the 
medical literature consulted and the judgement of the 
authors in interpreting it. However, Th e Extra Pharma-
copoeia is informed by knowledge of both medical re-
search and the medical marketplace, and it captures the 
‘state of the art’ free from the infl uence of hindsight. As 
a respected publication, it off ers a unique perspective 
on how knowledgeable practitioners in Britain under-
stood serotherapy in its formative years.
Antitoxins, serums and lymphs
Between 1895 and 1920 Th e Extra Pharmacopoeia list-
ed serum preparations that addressed 24 diff erent cat-
egories of disease or disorder (Table 1). Th e table shows 
the categories of serum products listed by their date of 
fi rst appearance in the special chapter devoted to anti-
toxins and sera. Categories shown in bold remain listed 
in the nineteenth edition of 1920. Th e other categories 
are displayed according to the date of the edition in 
which they last appeared, shown along the horizontal 
axis at the bottom. Categories shown in italics are var-
iants of anti-streptococcic serum.
Th e fi rst mention of antitoxins and serums occurs 
in the preface to the eighth edition of 1895 which, for 
the fi rst time, includes special chapters on ‘prepara-
tions from the animal kingdom, which till recently 
had been almost entirely neglected as curative 
agents’.20, 21 Such preparations are clearly diff erent 
from traditional remedies obtained from plants, and 
from chemical remedies of more defi nite composition, 
and have to be injected by hypodermic syringe. In the 
chapter titled ‘Antitoxins. Serums and Lymphs,’ anti-
toxins are fi rmly placed in the context of ‘the discov-
ery of the medicinal powers of the serum of animals 
which have been rendered immune to certain diseas-
es.’ 22
Th e longest section, on ‘Diphtheria Serum and An-
titoxin’, describes how horses are immunised and bled 
to prepare antitoxic serum ‘for use as a remedy, and as 
a prophylactic’. Its properties are summarised as fol-
lows:
Th is serum combats the disease in the human sub-
ject, and experience has shown that it can be safely 
injected into healthy children without causing any 
ill eff ects beyond an occasional appearance of urti-
caria.23
Laboratory studies are mentioned briefl y and there are 
extensive references to reports of clinical use, including 
the fi rst trials conducted in Germany, the earliest Eng-
lish cases, and large-scale French trials. Several produc-
ers are mentioned. Th e BIPM in London and the Pas-
teur Institute in Paris supply the serum ‘in its natural 
state but rendered aseptic’.23 In the former case, steri-
lized camphor is added. Aronson of Berlin makes a pat-
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1906 Cerebro-Spinal Fever Rheumatism Anti-Gonococcus Serum
Scarlet Fever Serum
1912 Hay Fever Serum
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ented preparation that has been purifi ed and concen-
trated, and is preserved by adding Trikresol (tricresol). 
Doses range from 1cc for prophylaxis in a child to 10cc 
for treatment. Behring and Ehrlich supply 10cc-doses 
in four strengths. Th e reader is cautioned to exercise 
care in comparing preparations made by diff erent au-
thorities, and at diff erent times, which ‘vary largely in 
strength’.23
A shorter section on ‘Tetanus Antitoxin’ credits Tiz-
zoni and Cattani in Italy with the idea of curing tetanus 
by an ‘animal extract’, briefl y describes how animals are 
rendered immune by repeated inoculations of ‘tetanic 
poison’ and gives references to clinical case reports. Th e 
assessment reads:
Th e general result has been to show that in acute 
cases, supervening at once on an injury, the antitox-
in has been useless; but that in cases where the onset 
is long delayed the antitoxin does exercise a control-
ling infl uence and such cases generally recover under 
its use.24
It is noted that no supply of English manufacture is 
available.
Another section refers to ‘Rabies Antitoxin’. Dogs 
were inoculated with the ‘rabies poison’ from spinal 
cord to set up immunity. An ‘anti-rabic virus’ was ob-
tained and then injected into patients with hydropho-
bia. Prophylactic use in people bitten by mad dogs is 
also mentioned. Th e judgment is equivocal:
Many successful cases were reported, but grave 
doubts have been thrown upon the treatment, and 
it has even been asserted that hydrophobia has been 
caused by this method.25
Th e description of Pasteur’s vaccine preparation as an 
antitoxin is misleading but understandable since the 
terms toxin, poison and virus are not distinguished and 
often used interchangeably. Use of the term vaccine is 
restricted to ‘Vaccine, Calf-Lymph,’ which is a prepara-
tion of cow-pox (Vaccinia virus) used for inoculation 
against smallpox, although this is not explained. A fur-
ther section, under the heading ‘Cholera Virus,’ refers 
to Haff kine’s ‘attenuated choleraic poison’ for protec-
tive inoculation.26
Other sections cover the use of bacterial products: 
fi rst, Coley’s use of toxins from Streptococcus erysipela-
tosus and Bacillus prodigiosus to treat sarcoma and car-
cinoma; and second, Koch’s ‘Tuberculin’ to treat tuber-
culosis and an extract called ‘Tuberculocidin Solution,’ 
the latter two included for the fi rst time in the previous 
edition of 1892.26





BIPM (London), Pasteur Institute 
(Paris), Aronson (Berlin), Behring 
& Ehrlich.
Various liquid and dried dosage 
forms in diff erent strengths.
1898 Products
Potency
‘Behring’s Extra Potent Serum’, 
‘Merck Serum’ and ‘French Se-
rum of Roux.’
Measured in standard ‘units of 
immunity.’
1901 Products ‘Serum Antidiphthericum’ (Phar-
macopoea Germanica).
‘Aronson’s Diphtheria Antitoxin’ 






Determined as neutralising power 
in Ehrlich-Behring units.
For therapy: 1,500-2,000 units, 
frequently much more injected.
For prophylaxis: 500-1,000 units; 
immunity claimed to last three 
weeks.
Inject antitoxin ‘at once’ without 
waiting for bacteriological diag-
nosis.
Use sterile syringe and needle, 
cleanse skin with ether soap, in-
ject in fl ank/scapulae.
Safer to give too many units than 
too few; ‘brilliant results’ ob-
tained by injecting iv.
Lower volumes of higher strength 




‘Serum Antidiphthericum’ (U.S. 
Pharmacopoeia), controlled by US 
government.
‘Solid Anti-Diphtheria Serum’ 
(Farmacopea Espanola) by evapo-
rating in vacuo.
Avoid wide-bore needle; warm se-
rum before injection; take care 
not to inject air.
Advantage of iv injection ques-
tioned; effi  cacy by oral and rectal 
routes disputed.
1908 Products ‘Serum Antidiphthericum, Liqui-
dum & Siccum’ (Pharmacopoeia 
Japonica). 
1910 Doses Lister Institute: initial dose in-
creases with lapse of time since 
onset of disease.
By second day, give 4,000-8,000 
units; by third day, 8,000-12,000 
units.
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Up to 20,000 units for a severe 
case now used at Eastern Fever 
Hospital.
Symptoms of ‘Diphtheria Serum 
Sickness’ are fever, rash, usually 
urticarial or variety of erythema 
multiforme.
More unpleasant eff ects include 
pain in joints, tendons and fasciae 
with fever.
Serum disease a familiar example 
of increased susceptibility or ana-
phylaxis.
Antitoxin no longer approved as 
prophylactic; indiscriminate use 
unjustifi able.
Antitoxins
Th e most important serum product in the period before 
the First World War is diphtheria antitoxin, which had 
been used successfully to treat acute cases of diphtheria 
in children. Table 2 shows the key developments in this 
category regarding changes in the product, its dosing, 
medical use, clinical benefi ts and side eff ects. Concerns 
about the variation in strength of serums made by dif-
ferent producers are refl ected in the defi nition of ‘units 
of immunity’ by 1898.27 By 1901 ‘Serum Antidiphthe-
ricum’ is an offi  cial remedy listed in the Pharmacopoea 
Germanica (fourth edition, 1900), followed by the 
Pharmacopoeia of the United States (offi  cial from 1905) 
in 1906, and subsequently others. By 1904 the strength 
of recommended doses is being quoted in terms of 
standardised antitoxin units.
In 1904 and 1906, the reader is given practical ad-
vice to use diphtheria antitoxin early and in suffi  cient 
quantities, and tutored in how to prepare and inject it 
safely. Although typically administered by subcutane-
ous injection, intravenous injections are also em-
ployed, though not without the criticism that they are 
more complicated to administer. Others attempt oral 
and rectal delivery, although claims of effi  cacy are dis-
puted.
Advantage is claimed for the use of higher potency 
serums owing to reduced side-eff ects. By 1910, the dos-
es employed have increased signifi cantly, especially in 
the case of delayed treatment. Diphtheria antitoxin for 
prophylaxis is fi rst fl agged in 1904, but by 1912 this use 
is frowned upon because of the side eff ects. For the fi rst 
time there is a detailed description of the disorder 
known as ‘serum sickness’, caused by hypersensitivity 
to horse protein with the attendant risk of anaphylaxis, 
and a caution regarding the indiscriminate use of anti-
toxin.
Table 3. Tetanus antitoxin: key developments, 1895-1912
Year Category Comments




Tizzoni & Cattani, Roux, 
Behring, and BIPM (London).
10-20cc every 6 or 12 hours, ac-
cording to the severity of symp-
toms.
1901 Use Intracerebral and subdural injec-
tion advocated by Roux & Borrel 
(Paris).







Lister Institute and Pasteur Insti-
tute supply liquid and dried anti-
toxin.
Should possess a potency of at 
least 1,000,000 Roux Units.
20-30cc subcutaneous at outset, 
followed by 10cc every 8 hours.
If time elapsed, 10cc intravenous, 
then 20cc subcutaneous every 8 
hours.
Administer antitoxin without de-
lay where slightest suspicion of 
tetanus.
For prophylaxis: excise wound, 
scrape out, and swab with iodine 
solution.
Repeat injection as immunity 
lasts 3 weeks vs 1-month incuba-
tion period for tetanus.
‘Dry pulverised Anti-tetanus Se-
rum’ recommended for dusting 
infected wounds.
Also used to treat infection of 




poea Belgica) with potency left to 
the manufacturer.
Lister Institute: at least 100cc 
subcutaneous, repeated next 2 
days, fi nal injection after 10 days. 
For prophylaxis: 20cc for lacerat-
ed wounds, especially when soiled 
with earth.
1908 Products ‘Serum Antitetanicum, Liquidum 
& Siccum’ (P. Jap.).
1910 Doses Lister Institute: 30cc urgently  in-
travenous, 100cc  subcutaneous 
(25cc into 4 separate parts of the 
body); repeat  subcutaneous dose 
on 2 following days; repeat  intra-
venous injection if no improve-
ment.
1912 Doses Even larger doses advised by some 
makers.
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In the case of tetanus antitoxin (Table 3), by 1898 
there are several producers on the continent as well as 
the BIPM in London. From this date, doses are typi-
cally quoted in terms of serum volume, although stand-
ard units are referred to when measuring potency from 
1904. Although tetanus antitoxin does not become an 
offi  cial remedy until the Pharmacopoea Belgica (third 
edition, 1906), like diphtheria antitoxin, it is available 
in both liquid and dried forms.
Given the diffi  culty of treating acute cases, intracere-
bral and subdural injections are being advocated in ad-
dition to subcutaneous injection in 1901. In 1904 the 
advice is to use antitoxin without delay at the slightest 
suspicion of tetanus, and to repeat subcutaneous doses 
regularly. When there is a delay after onset of symp-
toms, an initial intravenous dose is advised, followed 
by increased repeat doses. Th e intensity of recommend-
ed dosing increases in subsequent years. Th e use of tet-
anus antitoxin for the prophylactic treatment of pa-
tients with wounds is fi rst spelled out in 1904, as is the 
use of a dried serum to ‘dust’ soiled and potentially in-
fected wounds or the umbilical cord of at-risk new-
borns. Side-eff ects are not discussed, even as late as 
1912.
As far as rabies antitoxin is concerned, the 1898 edi-
tion mentions a specifi c serum antitoxin for rabies 
raised in animals in the conventional way by Tizzoni. 
After the next edition of 1901, however, there is no fur-
ther mention of antitoxins or serums for the treatment 
of rabies, although the original erroneous heading is 
retained in relation to Pasteur’s vaccine.
Serotherapy
In the 1898 edition the special chapter is renamed ‘An-
titoxins. Serotherapy’.11 References to lectures, discus-
sions and editorials are followed by a ‘Note of Caution’ 
in which the authors excuse themselves from making 
recommendations, advising physicians to heed the 
maker’s advice, and advises readers that
Th e constitution, mode of preparation and stand-
ards of strength of these serums, lymphs, and anti-
toxins of animal origin are still very indefi nite. Th e 
preparations obtainable at the present time are rare-
ly those which are referred to by physicians, even as 
to cases of last year. Th e modes of manufacture are 
still in process of development, and the results can-
not be estimated by chemical analysis any more than 
by physical processes; they can only be ascertained 
and compared by experiments on animals or on 
man.28
Th is disclaimer is retained until 1908, although both 
diphtheria and tetanus antitoxins are excluded from 
1901, refl ecting progress in standardising these two 
products.
Subsequent pages demonstrate a greatly expanded 
range for serotherapy, including ten new types of anti-
toxins and serums (see Table 1). Most widely used, un-
der the heading of ‘Septicaemia,’ are anti-streptococcic 
serums and antitoxins used to treat infections and min-
imise the risk of blood poisoning (Table 4). A variety 
of preparations is available for the treatment of several 
forms of fever and septicaemic infection, and new in-
dications are added in 1901. By 1904, it is noted that 
such infections may be due to organisms not recognised 
by anti-streptococcic serum. In addition, because dif-
ferent types of Streptococcus are responsible for diff erent 
diseases, for example Streptococcus pyogenes in erysipe-
las, it is recommended that serums should be ‘polyva-
lent’, that is ‘a mixture of several strains of the bacte-
rium have been employed for inoculation, so as to 
ensure the best all-round and uniform results’.29
An alternative to polyvalent serum is to make serums 
specifi c for the bacterial type(s) associated with each of 
the various streptococcal diseases. By 1906 a range of 
such disease-specifi c serums, including one for erysip-
elas, is commercially available. At this time, earlier 
treatment, larger doses, repeated administration and 
localised injection are being advocated. Treatment is 
further extended to diseases such as acute rheumatism 
and arthritis. Prophylactic use is suggested from 1898 
for specifi c cases where there is a risk of streptococcal 
infection and, later, prior to operations. Doses are al-
ways expressed in terms of the volume of serum rather 
than according to any standard. Although anti-strep-
tococcic serum remains listed in the nineteenth edition 
of 1920, no signifi cant developments are noted after 
1910.
A second category that persists until 1920 is Scla-
vo’s antitoxin to anthrax (Woolsorters’ disease), al-
though little new is noted after 1912. Another sort of 
antitoxin, Calmettes’s ‘anti-venene’ to counter poison-
ing by snake venom after the bite of the cobra, is ab-
sent from the special chapter on antitoxins after 1910 
but remains in later editions under the heading ‘Ser-
pent Venom,’ puzzlingly situated in a section of ‘Bac-
teriological Notes’.30
In the case of tuberculosis, it seems that good results 
are obtained in the treatment of some cases but, overall, 
anti-tuberculous serum (Marmorek’s) is not successful 
and appears for the last time in 1915. Antitoxic serum 
to the plague (Yersin’s Curative Serum) is still listed in 
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1915, but results are at best equivocal by 1906 and no 
further progress is reported afterwards. Attempts to de-
velop a curative anti-cholera serum appear to have 
largely failed by 1904, although repeated attempts are 
recorded up to 1912. Repeated claims are made of an 
antitoxin treatment for typhoid fever, but these are also 
largely unsuccessful by 1910.
In the case of cancer, various reports claim the use 
of ‘anti-cancer serum’ made by injecting animals with 
erysipelas or with the ‘juice’ from malignant growths. 
In 1906 a serum (Doyen’s) is made against Micrococcus 
neoformans, which is claimed to be present in portions 
of malignant tissue. By 1910 it is deemed that the ap-
proach is ‘not to be regarded scientifi cally’.31
More speculative work on remedies for leprosy and 
syphilis is dropped as early as 1901. Th e preparations 
involved in these cases – the use of leper’s blood to make 
an animal serum and the direct use of human serum 
from syphilitic cases – are examples of variations on the 
original approach of making immune serum by inocu-
lating animals with toxins or bacilli.
Th ere are several further additions to the serother-
apy arsenal between 1901 and 1906, though notably 
fewer than in 1898 (see Table 1). Among those that per-
sist are an anti-pneumococcic serum (Pane and Renzi’s) 
and a ‘bactericidal’ serum against colon bacillus to treat 
infections in urinary organs and as a prophylactic prior 
to operations. By 1910, in both cases, it is accepted that 
the existence of bacterial variants, which may share the 
same microscopic appearance and culture properties, 
may explain why attempts at cure fail. Other notewor-
thy developments, which occurred in relation to serums 
against dysentery and cerebro-spinal fever, are consid-
ered below in the section on the First World War.
Several new categories represent further examples 
of anti-streptococcic serums. In the case of scarlatina, 
there is a new specifi c serum (Moser’s) made by inocu-
lating horses with the products of culture of strepto-
cocci found in the majority of fatal cases, although an-
ti-streptococcic serum has been used in this disease 
since 1898 (see Table 4). Th e serum for scarlet fever is 
made through the agency of three forms of Streptococ-
cus. Anti-rheumatic serum (Menzer’s) is a polyvalent 
anti-streptococcic serum. Anti-gonococcus serum is de-
scribed as being anti-streptococcic and used to treat 
gonorrhoeal rheumatism.
With trypanosomiasis, early attempts to use serum 
from horses seem not to have worked out. In 1910 sug-
gestions are made to use instead the ‘highly immune 
serum’ of patients who have recently recovered or who 
have been given Atoxyl therapy (i.e. with the or-
ganoarsenic compound arsanilic acid).
Th e cure for inebriety proposed by Monsieur Broca 
of Paris, namely the injection of an ‘anti-alcoholic se-






Introduced by Marmorek; great 
variety of preparations in use.
BIPM supplies cases of three phi-
als of 10cc liquid or equivalent 
dry state.
Treatment of many forms of fever 
due to or associated with septicae-
mia.
Puerperal fever and septicaemia 
following childbirth treated with 
good results.
Also used to treat erysipelas, scar-
latina and endocarditis.
Prophylaxis: recommended in 
cases likely to involve risk of 
blood poisoning.
1901 Use Further use treating pyaemia, ve-




Anti-bacterial serum should be 
polyvalent.
Serum does not keep well and 
should be prepared fresh.
A few doses of 10-20cc should be 
given in any septic infection.
Infection may be due to organ-
isms not attacked by anti-strepto-
coccic serum.
In erysipelas, Streptococcus pyo-
genes is the organism responsible.
Prophylaxis: suggested before op-




Special sera for erysipelas, puer-
peral fever, scarlatina, endocardi-
tis and rheumatic fever obtainable 
commercially.
30cc in any form of septicaemia 
repeated daily until marked im-
provement.
In severe cases, must be given ear-
ly, in 20cc doses, at least twice in 
24h.
‘Large doses’ of serum advocated 
in threatened uterine infection.
Injection at seat of infl ammation, 
e.g. in erysipelas, produces good 
local eff ect.
Treatment of acute rheumatism 
and arthritis with some success.
1908 Use Indicated in simple septicaemia or 
sapraemia.
1910 Products ‘Metchnikoff ’s Serum’ used with 
favourable results in erysipelas.
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rum’ obtained from horses to which alcohol had been 
given is ‘received with smiling incredulity’ and never 
mentioned again!32
Scientifi c developments
Beginning with the ninth edition of 1898, the authors 
consulted a number of specialist texts: Immunity and 
Serum-Th erapy (1895) by George M. Sternberg, MD., 
surgeon-general with the U.S. Army; Serum Th erapy 
(1903) by Richard Tanner Hewlett, MD., bacteriologist 
to the BIPM and later professor of general pathology 
and bacteriology at King’s College, London; and Se-
rums, Vaccines and Toxines (1904) by W. Cecil Bosan-
quet, MD., physician to out-patients, Victoria Hospital 
for Children, London.33-35
A renamed chapter on ‘Antitoxins, Vaccines and 
Antitoxic Serums’ in the 1901 edition is revised with 
the assistance of (later Sir) German Sims Woodhead 
(1855-1921), professor of pathology at the University 
of Cambridge.12 He introduced a classifi cation of 
‘ “Anti” Serums’ [sic], which distinguishes antitoxic 
serums that neutralise toxins, principally anti-diph-
theritic and anti-tetanic serums, from ‘anti-bacterial’ 
serums that act directly on bacteria (the latter catego-
ry including ‘Cancer Anti-bacterial Serum’). In either 
case, the so-called ‘ “anti” body’ [sic] is the ‘immunis-
ing body’.
Th e chapter is substantially rewritten for the 1904 
edition and includes details of ‘important investigations 
and theories of various eminent bacteriologists’ such as 
Paul Ehrlich (1854-1915) and his ‘side-chain’ theory.36 
A distinction is drawn between the soluble toxins ex-
creted by diphtheria and tetanus bacilli and the toxins 
of typhoid and plague bacilli, which are inherent to the 
bacterial cell. In the latter case, two substances are 
needed: fi rst, the immunising body in the serum after 
exposure to the bacillus; second, the ‘complement’ pre-
sent in normal serum that brings about bacteriolysis. 
Lack of success with anti-typhoid and anti-cholera se-
rums is postulated to be due to a defi cit of complement 
in human blood, suggesting that adding fresh serum 
would be benefi cial.13
Accordingly, the edition of 1906 includes ‘Normal 
Horse Serum (Horse Plasma, Liquid)’ to provide added 
complement.14 It is also recommended as an ‘ideal food’ 
in typhoid and also useful for tuberculosis on the basis 
that the horse is immune to the disease. ‘Byno Plasma,’ 
a mixture of horse serum with malt extract, is a ‘tissue 
food’ to restore from collapse after parturition and for 
anaemia.37 In addition ‘Ox Plasma’ is recommended for 
infl uenza, to which the ox is resistant.38
Although ‘Hay Fever Serum’ – obtained by inject-
ing horses with ‘irritant toxins’ from grass pollen – ap-
pears in the chapter on antitoxins in 1912, it had ear-
lier been included as ‘Pollantin’ in 1904 under a 
secondary list of drugs.39 Th us, in fact, no novel cate-
gory of serotherapy product appears in Th e Extra Phar-
macopoeia from 1908 to 1920.
Vaccines and antitoxins
Th e edition of 1908 refl ects a shift in emphasis towards 
vaccines:
It is safe to say that Vaccine Th erapy of late has been 
in the ascendency, whilst the treatment with Anti-
toxic Serums has fallen back in some degree; at any 
rate it has not progressed for any disease with the 
exception perhaps of diphtheria, in which the injec-
tion of Antitoxic Serum is recognised as of vital im-
portance.40
Nonetheless, it is acknowledged that recent epidemics 
of cerebro-spinal meningitis in New York, Glasgow and 
Germany have ‘resulted in an advance of methods of 
diagnosis and treatment of that disease’.40 Th e dedicat-
ed chapter renamed ‘Vaccines and Antitoxins’ also as-
serts that treatment with antitoxic serums has given 
place to inoculation with the dead causative organisms 
of disease (therapeutic vaccination), treatment being de-
pendent on the concurrent estimation of Wright’s ‘Op-
sonic Index’.15
Sir Almroth E. Wright (1861-1947), director of the 
Department for Th erapeutic Inoculation, and patholo-
gist at St. Mary’s Hospital, London, had suggested that 
the body developed serum substances called ‘opsonins’, 
which coated microbes to make them more attractive 
to phagocytic white cells. He created laboratory meas-
urements of an opsonic index (later discredited) to 
monitor the immune status of patients and their re-
sponses to preventive and therapeutic vaccines.41 In-
creased space is devoted to describe both vaccines, in-
cluding tuberculins, and opsonins.42
Th is chapter refers to a new range of therapeutic 
vaccines from the Wimpole Institute, a private pathol-
ogy laboratory, as recommended by ‘an enthusiastic 
worker,’ Richard W. Allen (1876-1921), pathologist to 
the Royal Eye Hospital, London, and the author of Th e 
Opsonic Method of Treatment (1907).43 Dr Allen was re-
sponsible for preparing the vaccines issued by the Wim-
pole Institute, and the sole agency for the sale of ‘Wim-
pole Vaccines’ in England was none other than Mr W. 
Martindale, chemist.44, 45
Th e Preface to the 1910 edition, responding to 
claims that vaccine therapy would largely replace the 
pharmacy of the past, seeks to reassure the pharma-
cist:
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Personally we are not pessimistic as to the outlook 
for Pharmacy. Whatever happens, the most ardent 
opsonist will, we think, continue to use, e.g. narcot-
ic, purgative and febrifuge drugs, will employ local 
stimulants and internal and external antiseptics to 
diseased tissues and so forth ad lib., indeed in the 
Vaccines themselves which he uses, the opsonist does 
not ignore the action of Phenol as ‘preservative’.46
Th is edition provides a table of thirteen kinds of thera-
peutic vaccine to bacterial diseases, including cerebro-
spinal fever, Coli bacillus, Pneumococcus, Streptococcus, 
tuberculosis and typhoid, which are potentially com-
petitive with antitoxins and serums; and many others, 
such as Staphylococcus, for which no serotherapy is evi-
dent.47 By 1912, as it continued to expand, Th e Extra 
Pharmacopoeia required division into two volumes; vol-
ume I contains the chapter on vaccines and antitoxins 
with seven new vaccines listed including cholera and 
diphtheria.17 In 1915, there was one addition.18 By 1920, 
the total was twenty-fi ve, including a new vaccine for 
dysentery.19 Further doubts had been cast on serums in 
1910:
With the exception of antidiphtheritic and antite-
tanic serums, the question is asked whether the prep-
aration of the various antibacterial serums is based 
on exact scientifi c principles.48
Th is caution is grounded in the theory that interaction 
between the dead micro-organisms in a vaccine and the 
body’s tissues releases opsonins and other anti-bacteri-
al substances into the bloodstream to incite white cor-
puscles to devour invading microbes:
Th e Antitoxins in a serum probably act simply by 
neutralising an equivalent amount of toxin – any 
further action being due to the presence of dead mi-
cro-organisms in the serum, which act as a feeble 
vaccine.49
Growth in the importance of serum and vaccine 
therapies
Th e growth of serum and vaccine therapy between 1895 
and 1920 can be gauged by comparing the number of 
pages of the chapter in Th e Extra Pharmacopoeia devot-
ed to these preparations with the number of pages un-
der the traditional heading of ‘Materia Medica’. Th e 
number of pages devoted to antitoxins, sera and vac-
cines as a percentage of the pages devoted to materia 
medica in successive editions over this period is illus-
trated in Figure 1.
In the 1895 edition materia medica makes up 435 pag-
es, or 75 per cent of 581 pages, excluding 28 introduc-
tory pages. Th e chapter dealing with serums and vac-
cines is 12 pages long, which is just less than 3 per cent 
of the space taken by materia medica. By 1901, the pro-
portion had doubled to nearly 6 per cent, refl ecting in 
part the growth of interest in serotherapy and the sig-
nifi cant number of new serum preparations introduced 
over this time. Until 1906 the title of the chapter listed 
antitoxins ahead of vaccines.
From 1908, when the chapter title was headed by 
vaccines, the proportion rose higher once more, reach-
ing a peak of more than 10 per cent in the 1912 edition, 
Figure 1. Th e growth of serum and vaccine therapy in 
Britain, 1895-1920






Number of immunising units per 
cc varies among pharmacopoeias/
manufacturers.
General opinion against use of 
antitoxin per anum and per os.
‘Prophy lac t ic  Dipht her i a 
Antitoxin’/‘M.M.I.’ (Behring): a 
mixture of diphtheria toxin with 
antitoxin in suitable proportions, 






– preparation of ‘antidiphtheritic 
globulins’ purifi ed by removing 
serum albumen.
Use of purifi ed antitoxin may re-
duce untoward serum rashes.
https://doi.org/10.24355/dbbs.084-202007300928-0
 PHARMACEUTICAL HISTORIAN  ·  2019  ·  Volume 49/2 41
refl ecting in part the increasing interest in therapeutic 
vaccines and the number of new preparations intro-
duced over this time frame. Volume I of this edition 
comprised 1,114 pages (excluding 39 pages of introduc-
tion) of which 791 pages cover materia medica, repre-
senting about 70 per cent of the total, the average over 
the whole period. Between 1895 and 1912 the number 
of pages devoted to serums and vaccines increased sev-
en-fold in absolute terms.
Th e First World War
Although the fl ow of new antitoxins and serums had 
eff ectively dried up by 1906, Martindale and Westcott 
did refl ect the signifi cant strides made in the use of 
some existing types of preparation that gained renewed 
importance during the First World War. Table 5 sum-
marises developments with regard to diphtheria anti-
toxin during the period 1915 to 1920.
Th e 1920 edition contains much new information 
about tetanus antitoxin (Table 6). Th e strength of anti-
tetanus serum is now described in terms of U.S.A. 
units. For therapy, the Lister Institute advocates very 
large and repeated doses intraspinally, as well as by sub-
cutaneous, intravenous and intramuscular injection. In 
the latter case, it is advised to ascertain if the patient 
has any idiosyncrasy such as asthma induced by sensi-
tivity to horses. For the treatment of wounds, an injec-
tion of antitoxin is advised in every case where there is 
a possibility of infection, ‘experience gained in the fi rst 
year of the war’ confi rming that 500-1,000 units is a 
suffi  cient prophylactic dose for most cases.50 Given the 
extreme measures necessary to treat a case of tetanus, 
stopping the disease from developing in the fi rst place 
is the preferred option.
A notable development by this time is a concentrated 
form of tetanus antitoxin, listed in the United States 
Pharmacopoeia as ‘Serum Antitetanicum Purifi catum’. 
Th ere is also the analogous ‘Serum Antidiphthericum 
Purifi catum’. During the purifi cation of the antitoxic 
globulins present in serum, a signifi cant quantity of ir-
relevant serum albumin is removed, reducing the 
amount of horse protein responsible for side-eff ects and 
so reducing the chance that serum sickness will occur. 
Th e edition of 1915 already warns that serum treatment 
‘may render the patient anaphylactic or hypersensitive 
to future injections of serum from that animal from 
which the antiserum was prepared’.51
An anti-dysenteric serum is available from the Lister 
Institute by 1906 (Table 7). Doses are quoted in terms 
of volume rather than according to any standard. By 
1910, the serum is being raised against multiple strains 
of the dysentery bacillus, greater doses are recommend-
ed for serious cases, and intravenous injection advocat-
ed. Following the war, larger doses still are being advo-
cated for the therapeutic treatment of bacillary 
dysentery, which was the main cause of epidemic dys-
entery on the Western Front, and much larger doses 
intravenously for the most serious cases.
Anti-meningococcus serum has been developed in re-
sponse to an epidemic of cerebro-spinal fever in New 
York (Table 8). Doses are given in terms of volume. By 
1910, large doses are employed intraspinally with some 
success and without untoward side-eff ects. Th e serums 
available at the onset of war proved of little value. How-
Table 6. Tetanus antitoxin: key developments, 1915-1920
Year Category Comments
1915 Products ‘Tizzoni’s Serum,’ a special prepa-






‘ S e r u m  A n t i t e t a n i c u m 
Purifi catum’/‘Concentrated Teta-
nus Antitoxin’ (U.S.P.).
Strength of antitoxin commonly 
determined in terms of U.S.A. 
units.
Lister Institute: ‘very large doses 
energetically and continuously’ at 
the fi rst sign: 3-8,000 units by 
lumbar puncture; 9-16,000 units 
iv; 10,000 units im & sc.
If patient worse after 18h, repeat 
intraspinal dose daily for 3 or 4 
days, also iv & im if required; bet-
ter to give too much than too lit-
tle.
On improvement, give 1,500-
4,000 units sc twice daily for sev-
eral days.
For prophylactic treatment of 
wounds: at least 500 units given 
under the skin of the abdomen or 
fl ank in every case of injury where 
a possibility of infection.
If much soiling of the wound, or 
48h has elapsed, 1,000-1,500 
units and further dose of 500 
units in a week.
Experience gained in the fi rst year 
of the war confi rmed that 500-
1,000 units is a suffi  cient prophy-
lactic dose for most cases.
Prophylactic use is best.
Before iv injection, inquire if pa-
tient has any idiosyncrasy such as 
liability to attacks of asthma in-
duced by sensitivity to horses.
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Claimed to have reduced mortal-
ity of epidemic dysentery.
Preliminary experiments on pro-






Lister Institute: serum made 
against the dysentery bacillus 
(Shiga and Kruse types) and toxic 
substances elaborated by the ba-
cillus.
From 20cc subcutaneous up-
wards, according to severity.
For prophylaxis: 20cc subcutane-
ous.
Treatment lately more extensively 
tried; results on the whole not 
convincing.
Pains and temporary rashes may 




Lister Institute: serum against 
multiple types (Shiga, Kruse, 
Flexner, Duval etc.).
For a grave case, 50cc subcutane-
ous; in very grave, 80-100cc; for a 
child, half these doses; by intrave-
nous, not more than 50cc at one 
time.
Stools return to normal rapidly in 
successful cases, but treatment to 
continue.
In ulcerative colitis, serum which 




Serum appears to retain its toxin-
neutralising power for at least 1½ 
years.
In the fl ank: 80cc for severe, or 
40-60cc for mild cases of bacil-
lary dysentery;
or, 100cc intravenous without de-
lay followed by a second dose 
within 24hours;
or, 60-80cc  intravenous, once or 
twice daily, for the fi rst 3 days.
In ‘fulminating’ cases, much larg-
er doses, assisted by magnesium 
sulphate.
Table 8. Anti-meningococcic serum: key developments, 
1906-1920
Year Category Comments
1906 Products ‘Anti-Meningococcus Serum’ 





supplied in 10 and 25cc vials.
10cc repeated once or twice with-
in a few days; stated to ward off  
relapses.







‘Flexner and Jobling’s Antimenin-
gitis Serum:’ good results ob-
tained.
Intraspinal injection under chlo-
roform: use rigid and compara-
tively large trocar; drain fl uid af-
ter puncture; increase fl ow by 
raising patient’s head and shoul-
ders. Intraspinal serum appears to 
shorten the disease and reduce 
mortality. Injected hypodermical-
ly, serum did not produce any 
marked eff ect.
If very severe: 30cc or more every 
day for 3 days. In less urgent cas-
es: sometimes a single injection of 
30cc is valuable.
Largest amount in a single case: 
210cc intraspinally.
No undesirable symptoms follow 
the use of serum.
‘Wassermann’s Serum:’ numerous 
recoveries. Also, a highly immune 





Serum available at start of epi-
demic on Western Front found to 
be of little value.
1915 serum made from current 
epidemic strains had considerable 
curative potency.
‘Antimeningococcic Serum New 
(1916)’ of the Lister Institute.
Lister serum: 30cc at earliest mo-
ment, repeated daily for at least 4 
days if possible; intrathecally and 
intravenously successful.
Flexner serum: lumbar puncture, 
drainage and intrathecal injection 
of polyvalent anti-meningitis se-
rum most useful treatment.
In the Navy, intrathecal injec-
tions showed largest percentage 
recoveries.
ever, freshly prepared serums made against meningo-
cocci isolated from patients with cerebro-spinal fever in 
the current epidemic are eff ective. Th e subsequent iden-
tifi cation of four meningococcal types ensures that se-
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rums have improved curative potential. Th e procedure 
involves lumbar puncture, drainage of cerebro-spinal 
fl uid, followed by intrathecal injection of polyvalent se-
rum, repeated as necessary.
Antibodies, the imitations of serum therapy, and 
combined treatments
A new sub-section of the 1912 edition headed ‘Antibod-
ies’ defi nes the term antibody for the fi rst time as ‘a sub-
stance found in the blood serum as result of the pres-
ence in the blood of a foreign proteid [sic] termed its 
antigen’ and emphasises that antibodies are always spe-
cifi c for their antigen. Th us, when the toxin of diphthe-
ria acts as the antigen, it leads to the production of 
diphtheria antitoxin, which has no action on the toxin 
of tetanus, for instance.
Antibodies are classifi ed by the eff ect produced on 
combining with their corresponding antigen: antitoxin 
neutralises toxin, ‘precipitin’ precipitates antigen, ‘ag-
glutinin’ causes cell clumping, ‘cytolysin’ prepares cells 
for solution by complement, and opsonin prepares cells 
for ingestion by phagocytes (though not all opsonins 
are necessarily antibodies). Th is new section explains 
the diff erence between ‘natural and acquired immuni-
ty’, and the important distinction between the ‘tempo-
rary or passive immunity’ conferred by serum and the 
‘active immunity’ induced by vaccines.
Th e next edition of 1915 highlights some of the dis-
advantages of serum therapy. Because certain types of 
bacillus have many diff erent types of member, antibod-
ies effi  cient against one member may be altogether 
without eff ect on another member of the family. Poly-
valent serums have had some success, but many failures 
may still be ascribed to this diffi  culty. Further, the im-
munity added by the use of a serum is limited in kind 
and extent. Antiserums with a high content of antitoxin 
contain little ‘bactericidin’, lysin or opsonin, hence they 
may neutralise the toxins circulating in the patient’s body 
but exert little or no eff ect on the infective agent.
A solution to the limited and temporary immunity 
conferred by the transfer of antibodies is treatment in 
combination with vaccines. In 1910 there is a report of 
a polyvalent anti-streptococcic serum given to a patient 
while an individual vaccine is being prepared. In 1912 
a vaccine against Bacillus diphtheriae is advocated as an 
adjuvant to the use of diphtheria antitoxin. Th e 1915 
edition refers to a ‘prophylactic’ diphtheria antitoxin 
developed by Behring, which consists of a mixture of 
toxin and antitoxin in suitable proportions such that 
the toxin is neutralised yet still capable of acting as a 
vaccine.
A new sub-section in 1915 describes ‘Sensitised Vac-
cines (Sero-Vaccines)’, which are bacterial vaccines 
treated with the corresponding antiserums prior to use. 
Th e idea was that pathogenic bacteria exposed to im-
mune serum containing numerous specifi c antibodies 
of diff erent types would lose their virulence and become 
more readily phagocytosed. In certain instances, the 
manufacture of such vaccines employs antiserums de-
rived from horses or calves; in other cases, human se-
rum isolated from patients who had been highly im-
munised against the corresponding bacterium is used.
Sero-vaccines are perceived to have several advan-
tages: minimal risk of overdosing, no local or general 
reaction, and rapid stimulation of immunity, making 
them ideal for use in acute, severe and emergency situ-
ations. Th ey also have disadvantages: the degree of im-
munity attained is lower, their preparation risks con-
tamination by other pathogens, and they keep less 
well.
In 1920 a special mention is also given to ‘Gibson’s 
Sensitised Dysentery Vaccine,’ which was developed by 
the late Captain H. Graeme Gibson (1883-1919) of the 
Royal Army Medical Corps (RAMC). Since the stand-
ard approach had failed to produce an eff ective vaccine, 
Gibson reasoned that certain antibodies in anti-dysen-
tery serum had rendered the bacteria antigenically in-
ert. Martindale and Westcott note that
To overcome the diffi  culty he absorbed these sub-
stances from the serum and after satisfying himself 
that the removal of the antibacterial substances from 
the serum did not interfere with its antitoxic action 
he gave the vaccine with this absorbed serum. Vac-
cines so treated led to very little reaction in man and 
laboratory tests showed that protective substances 
were formed in the blood.52
Discussion
Th e 1895 edition of Th e Extra Pharmacopoeia intro-
duced a diverse range of preparations which were de-
scribed using nomenclature that was potentially con-
fusing given that the science of immunity was still at 
an early stage. Some were vaccines derived directly from 
known bacilli, or the unknown agents of disease later 
known as fi lter-passing viruses, with or without passage 
through animals. Others involved the use of bacterial 
cultures to induce immunity in a variety of species of 
animals to derive an antitoxic serum. In the case of 
diphtheria, such preparations had multiple sources, 
came in diff erent forms, and varied in potency.
Diphtheria antitoxin is the remedy most closely 
identifi ed with the history of serum therapy because of 
its success in tackling the childhood scourge of diph-
theria.53 Th e Extra Pharmacopoeia refl ects how it was the 
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fi rst serotherapy to be widely developed and tested, 
commercialised and regulated, standardised and made 
offi  cial. Wide experience of its use in the lead up to the 
First World War allowed an understanding of how to 
dose and deliver antitoxins eff ectively for therapy, how 
to use them for prevention of disease and, later, how to 
minimise the risk of side eff ects. However, diphtheria 
antitoxin was by no means typical. Th us, from the ear-
liest days, it was clear that tetanus antitoxin was not ef-
fective in acute cases and so its development proceeded 
more slowly and along diff erent lines.
It is perhaps unsurprising that the emergence of a 
new approach to therapy should have been quickly and 
widely exploited, leading to the introduction of many 
novel preparations intended for the treatment of diverse 
infections and a number of other disorders where there 
was some rationale, however shaky, to attempt serother-
apy. Speculative approaches, which we might today 
judge to be of dubious scientifi c or ethical quality, 
quickly failed to take off . Th ose with little or no effi  -
cacy were generally viewed with doubt and often 
dropped soon after.
In the case of common or diffi  cult-to-treat diseases 
such as tuberculosis, pneumonia and cancer, the hopes 
for serum therapy lasted longer. In contrast, for epi-
demic diseases such as cholera, the plague and typhoid, 
the role for serums was less clear given the development 
of preventive vaccines designed to control outbreaks. 
For rare problems such as anthrax and poisoning by 
snakes, where there was no alternative remedy, serum 
preparations seem to have persisted despite little inno-
vation that was deemed noteworthy.
Scientifi c developments noted between 1901 and 
1906 identifi ed some of the limitations of serum ther-
apy. Many preparations, such as the various serums 
for septicaemia, did not appear to act by the strictly 
antitoxic mechanism that proved successful in the case 
of diphtheria. Th us, anti-bacterial serums typically 
had either to be polyvalent, to cover multiple strains 
of bacteria, or to be specifi c to the type of bacillus 
causing a particular type of infection. Even then, such 
serums might not kill the bacteria they recognised 
without added complement and they were, in any 
case, expected to be only partially eff ective in cases of 
mixed infection.
During this period, the concept of serotherapy was 
far from homogeneous and instead encompassed at 
least four distinct approaches: (i) antitoxic serums made 
by inoculating animals with toxin, poison, virus, ven-
om, pollen or alcohol; (ii) anti-bacterial serums from 
animals immunised using preparations of bacteria/cell 
extracts; (iii) serum from animals naturally resistant to 
disease and thought to contain protective substances; 
and (iv) intravenous serum taken from patients recu-
perating from disease and therefore believed to have 
developed immunity to the infecting organism.
Enthusiasm for serotherapy had already waned by 
1906 before the advent of therapeutic vaccines, which 
were purported to engage the phagocytic power of the 
white blood cells in a way that antibodies could not. As 
such, therapeutic inoculation could be viewed as di-
rectly competitive with serotherapy. However, after the 
main wave of new vaccines that lasted until about 1912, 
the two approaches seem to have co-existed and com-
bined in a pragmatic and innovative fashion – vaccine 
as adjuvant to antitoxin, toxin-antitoxin mixture as vac-
cine, and novel sero-vaccines – designed to improve 
their therapeutic action.
Serum therapy continued to develop, however, re-
ceiving a boost in the First World War. Tetanus anti-
toxin had a truly antitoxic mode of action, but the char-
acteristics of the disease made therapy a tough 
proposition that required aggressive treatment to have 
a chance of success. Th e problem of infection of trau-
matic injuries emphasised the value of prophylactic 
treatment of contaminated wounds with standardised 
antitoxin. Prevention was the preferred option even 
with the risk of side-eff ects including potentially fatal 
anaphylactic shock.54
Two other forms of serotherapy grew in impor-
tance in Britain during the war – anti-dysentery and 
anti-meningococcal serums – because the War Offi  ce 
ordered signifi cant quantities for use by the RAMC.55 
In the case of dysentery, bacteriologists had largely 
worked out strain variation prior to the war so that 
polyvalent serum was already the norm. By contrast, 
the understanding of meningococcal strains was 
shown to be incomplete and new research was re-
quired to allow producers to develop eff ective polyva-
lent serums for the treatment of patients with cerebro-
spinal fever caused by the meningococcal types 
prevalent during the war.
An important trend that can be discerned for the 
principal antitoxins and serums is a move to increas-
ingly aggressive treatment: the use of greater doses or 
volumes of serum, given to the patient earlier and more 
frequently; these doses administered intravenously or 
by a variety of routes, some local to or allowing better 
access to the seat of disease; such doses in addition to, 
or instead of, sub-cutaneous injection. Dose infl ation 
may have resulted, on the one hand, when physicians 
gained greater confi dence in using serotherapy, though, 
on the other, serum preparations likely lacked suffi  cient 
potency in many cases. Th e complexity of the antibod-
ies later recognised to be present in anti-bacterial se-
rums, and uncertainty regarding their precise roles in 
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immunity, made it diffi  cult to establish proper stand-
ards by comparison with antitoxins.
Th e path followed by any one type of antitoxin or 
serum will have been infl uenced by many factors in-
cluding the nature of the disease, the scale of the med-
ical problem, the status of scientifi c knowledge, the 
availability of other treatments, and the eff ectiveness of 
public health measures. Histories of serum therapy have 
tended to focus on products that address individual dis-
eases, especially in the United States or Europe.56-58 Al-
ternatively, the development of the fi eld has been con-
sidered, often on a case-by-case basis, in the wider 
context of vaccination or the treatment of infection.59-61
Th is article instead off ers a broad perspective of the 
status of serum therapy and the dynamic changes that 
occurred in Britain in the period from 1895 to 1920 
during which the understanding of infectious and oth-
er diseases was evolving, judgement of treatment effi  -
cacy was largely subjective, and outcomes were uncer-
tain. Serum therapy was pursued because it off ered a 
specifi c remedy for unmet medical needs. One hundred 
years later, serotherapy and its off shoots remain a valid 
mode of treatment: the current edition of Martindale 
lists several antitoxins, including diphtheria and teta-
nus, as well as several other antiserums and immuno-
globulins.62
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A R T I C L E
Arthur Rowan (1896-1971): A humanitarian during 
the Japanese occupation in colonial Hong Kong
Patrick Chiu
Abstract 
Arthur Rowan, a pharmacist of Eurasian ancestry, em-
bodied fearlessness and selfl essness throughout an ex-
tremely challenging period during the Japanese occu-
pation of Hong Kong between 25 December 1941 and 
15 August 1945. During the three years and eight 
months of occupation by the Imperial Japanese Forces 
in this British colony, western pharmacy practice was 
disrupted and black market activities by unscrupulous 
traders were rampant. Arthur Rowan was the only 
pharmacist who had not fl ed the territory and was not 
held at the Japanese internment camp. Despite living 
in constant fear and danger, Rowan was able to smug-
gle medicines into the Stanley internment camps for 
those who needed them for life threatening conditions.
1941 12 25 1945 8 15
(Arthur Rowan)
Introduction 
In the fi rst half of the twentieth century the Hong 
Kong colonial elite consisted of individuals ranging 
from colonial administrators to business and industrial 
leaders of British, Chinese and Eurasian ethnic groups, 
and they formed the backbone of the ruling class.
Arthur Rowan (his Cantonese name was Lau Chun 
Lun) was a Eurasian of the Anglican faith. He adopted 
the Chinese surname Lau based on the maiden name 
of his paternal grandmother. His father, Th omas Row-
an, also a Eurasian, passed away when he was only ten 
years old, leaving Arthur and his two brothers to be 
raised by their mother with the help of her family.
Arthur grew up as a true gentleman of his time, em-
bracing both British and Chinese culture, and he served 
the community selfl essly as a humanitarian during the 
Japanese occupation of Hong Kong between 1941 and 
1945. After eighteen days of fi erce fi ghting, and after a 
loss of 1,500 troops (or 10 percent of the 15,000 strong 
Allied Forces led by Major-General Christopher Malt-
by), the Governor of Hong Kong, Mark Aitchison 
Young, surrendered to Lieutenant General Takashi 
Sakai of the Imperial Japanese Forces at the Peninsula 
Hotel in Kowloon on 25 December 1941 (Figure 1).
Figure 1. Surrender of the Allied Forces in Hong Kong on 
25 December, 1941 (Source: Hong Kong Public Records 
Offi  ce)
Hong Kong in 1941: population, fi nance and econ-
omy 
Th e population of Hong Kong dropped from 1.8 mil-
lion in December 1941 to 1 million by the end of 1942, 
and then below 600,000 within three years and eight 
months under Japanese rule. 1 A target population of 
500,000 was initially set by the Japanese, with a strategy 
of forced repatriation to defl ate the population against 
an anticipated counter-attack by the Allied forces.
Mass exodus occurred, during which local residents 
and British civilians who managed to  escape from the 
civilian internment camp in Stanley, Hong Kong Island 
(which was modifi ed to accommodate 2,800 western 
civilian detainees) fl ed to anywhere in China that was 
free of Japanese forces. Th e exodus was prompted by 
starvation, hyper-infl ation, on-going food shortages, 
and constant fear of execution due to non-compliance 
with military rules. In an article in 1996 Archer and 
Fedorowich explain that:
Th ere was one civilian camp and three prisoner-of 
war (POW) camps in the territory of Hong Kong. 
All the colonial administrators, including their fam-
ily members, became internees in Stanley, on Hong 
Kong Island, which numbered at 2,800; an estimat-
ed 2,325 to 2,514 were British. Th e adult popula-
tion numbered at 1,370 men and 858 women, and 
children 16 years of age or younger numbered at 
286, 99 of whom were below the age of four. 2
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Although medical facilities were inadequate, the intern-
ees counted amongst their number about 40 doctors, 
2 dentists, 6 pharmacists, 100 trained nurses, and a 
large number of volunteer auxiliary nurses.3 Because of 
this, according to historian G. B. Endacott, no major 
epidemic occurred within the Stanley internment 
camp.4 Th e other three POW camps with over 7,000 
internees were all located in Kowloon; one in Argyle 
Street housing military offi  cers, one in Sham Shui Po 
for other ranks, and the third at Ma Tau Chung for In-
dians. Beri-beri (at least 600 cases were reported) and 
pellagra were the two common diseases in the Sham 
Shui Po camp due to poor food supply, resulting in mal-
nutrition and constant ill-health.
Th e economy was in a shambles within six months 
of military occupation, with the local currency depre-
ciating by 75 percent against the Japanese Military Yen, 
which severely jeopardized and interfered with daily 
economic activities. Factories were taken over by the 
Japanese for wartime production of essential commod-
ities, forcing many factory owners and unemployed 
workers to fl ee Hong Kong. Oswald Cheung, the eldest 
son of a Chinese father and a Jewish mother of the Kad-
dorie family of Iraqi origin, recalled the harrowing days 
under Japanese occupation:
In August 1942 my family ran out of money. In 
Hong Kong my father, who had worked for Shell 
since he graduated from the university, found him-
self out of a job. As for money in the bank, the Jap-
anese allowed withdrawals of one quarter of depos-
its, and later by another 25%, leading to a rate of 
four dollars to one military yen.5
Diseases and epidemics, medical and public health, 
and pharmaceutical services 
On 18 November 1943, Th e Hong Kong News – a daily 
newspaper sanctioned by the Japanese military admin-
istration – reported as follows:6
Th e diligent and painstaking eff orts of the Japanese 
authorities in the prevention of any outbreak of ep-
idemics, as compared to the slovenly attitude of the 
former British government in Hong Kong, are clear-
ly shown in the following table [Table 1], which is 
displayed in the show window of Matsusakaya.7
Th e Japanese claimed no serious epidemic occurred in 
Hong Kong except cholera in 1940 and 1943 (the fi f-
teenth year of Showa8) with 945 and 211 aff ected cases 
respectively, and 626 and 105 fatal cases respectively. 
Indeed, the major causes of death were due to malnu-
trition, malaria, cholera, typhoid, dysentery, diphtheria, 
and meningitis. Sanitary control became seriously dis-
rupted with irregular collection and disposal of refuse 
and night soil, failure of the supply of fl ushing water 
owing to the loss of electrical power pumps, and dam-
Table 1. Cases of infectious diseases reported by Japanese 
authorities 1940 and 1943









Cholera aff ected 945 211
Cholera fatal 626 105
Diphtheria aff ected 335 nil
Diphtheria fatal 270 nil
Scarlet fever aff ected 22 nil
Scarlet fever fatal nil nil
Typhoid fever aff ected 410 294
Typhoid fever fatal 155 31
Dysentery aff ected 1,343 191
Dysentery fatal 325 56
Meningitis aff ected 268 2
Meningitis fatal 89 1
age to drains and sewers from bombing and shell fi re, 
and failure to chlorinate water. An alarming state of 
widespread acute infections prevailed.
Other diseases resulting from defi ciencies and supply 
failures included Beri Beri, tuberculosis and leprosy. 
Venereal diseases became widespread, and the main 
factors contributing to an alarming rate of infections 
were the closure of social hygiene clinics, interruption 
in the supply of anti-venereal drugs, and the rampant 
prostitution of local women by will or forced upon 
them as ‘comfort women’ by the invading troops.9, 10
A public health department was formed under the 
Civil Department of the Japanese Army on 1 January 
1942 under Major-General Yazaki.11 Dr P. S. Selwyn-
Clarke, the director of Medical and Health Services 
prior to the Japanese occupation, summarized what 
happened in his report:
On 1 January 1942, a Japanese Medical Department 
came into being (at least on paper) under Colonel 
T. Eguchi, but the bulk of the administrative and 
executive work continued to be carried out until the 
end of February 1942, when all European members 
of the department – with the exception of a small 
skeleton cadre – were interned following the escape 
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into China of Dr Gordon King. Th is group consist-
ed of two health offi  cers, one medical offi  cer, six 
sanitary inspectors, the accountant, and the writer 
who was appointed ‘adviser’. Th e Asiatic elements in 
the department suff ered a very considerable reduc-
tion, for most of the Chinese doctors, nurses, dress-
ers, dispensers, clerks, etc. were naturally reluctant 
to serve in Hong Kong under Japanese control. 
Th e report continues:
For sixteen months the struggle to maintain such 
services went on, but eventually it was brought to an 
abrupt ending on 2 May 1943 by the arrest and the 
imprisonment of the writer for alleged anti-Japanese 
espionage and by the internment in Stanley Civilian 
Internment Camp of the remainder of the British 
and European staff  three days later. From that date, 
the activities of the Department became progres-
sively restricted so that when the collapse of Japanese 
resistance occurred in the middle of August 1945, 
there were very few hospitals, no welfare centres and 
practically no public dispensaries remaining open to 
the public while town cleansing and similar activi-
ties had become things of the past. On 1 September 
1945 control was regained, although several days 
earlier the writer had contacted loyal members of the 
former staff  to ensure that no gap occurred in the 
administration and that few still remaining in Hong 
Kong (under the writer’s administrations) were ready 
to start on reconstruction work immediately after 
the Japanese were removed to concentration camps.12
In his account, G. B. Endacott also described the ac-
tivities of clinics and hospitals that valiantly remained 
open during the Japanese occupation:
Th ere were few hospitals available to civilian popu-
lation. Th e Japanese army took over Kowloon Hos-
pital and the temporary hospital in the Central Brit-
ish School, and the British wounded were moved to 
St. Th eresa Hospital until 1943 when this was taken 
for the Japanese sick. Queen Mary Hospital was 
used as a Japanese military hospital and then as a 
military barrack. Th e Japanese navy used the Tung 
Wah Eastern Hospital. Dr. Selwyn-Clarke induced 
the Japanese to re-open Sai Ying Poon and Tsan Yuk 
Hospitals but they were closed again in 1944, and 
the Kwong Wah Hospital and some small private 
hospitals were the only ones open to the Chinese 
community during the whole period. Th e old public 
clinics and dispensaries were closed, but eventually 
the Japanese began a scheme of free medicine for the 
poor and one hundred free beds were made available 
at the Kwong Wah Hospital, and by May 1945 there 
were thirty-eight free treatment dispensaries.13
Th e service of Dr. Selwyn-Clarke was terminated when 
his original sponsors – Col. T. Eguchi, aide to the Jap-
anese Military Governor, and Mr Oda, the head of Jap-
anese Foreign Offi  ce Staff  – were transferred out of 
Hong Kong in the early spring of 1943, with Dr Kirib-
ayashi appointed as the Chief of the Medical Depart-
ment. He was arrested by the Kempeitai (the Japanese 
military police similar in function to the German 
Gestapo in the Second World War) and was accused of 
being an undercover spy for MI9,14 (the British Direc-
torate of Military Intelligence Section 9, a department 
of the War Offi  ce between 1939 and 1945) in May 
1943.15
Th e clinics and hospitals under the Roman Catho-
lic Church, which included the Sisters of the St. Paul’s 
of Chartres, the Canossian Sisters and the Sisters of Pre-
cious Blood, amongst others, continued their services 
in cases of hardship, and provided free clinics for the 
poor throughout the period of Japanese occupation, 
with the exception of St. Paul’s Hospital which was 
closed soon after an accidental bombing by the Allied 
Forces in April 1945.
Lewis John Morley, chief pharmacist of the colonial 
government, and his family were interned at the Stan-
ley internment camp during the war. Some dispensing 
staff  stayed on, and a few – like Ulian Khoo,16 a dis-
penser who worked at the Queen Mary Hospital before 
the Second World War – fl ed to Chungking (now called 
Chongqing), the war-time capital of Republican China. 
Arthur Bentley, a pharmacist and lecturer in Hong 
Kong who escaped in February 1942, had an appoint-
ment at the National School of Pharmacy (NSP) in 
Chungking.17
Many western pharmacies were closed, since most 
expatriates including western doctors and pharmacists 
were either interned or departed soon after the Japanese 
occupation. Supplies of western drugs were mainly 
from Japan, and were only available on the black mar-
ket at exorbitant prices. Furthermore, the practice of 
Traditional Chinese Medicine (TCM) was more hard 
hit since fresh supplies of herbal drugs from the main-
land were not available.
Arthur Rowan’s humble beginnings and his noble 
humanitarian cause 
Arthur Rowan was born on 30 June 1896 in Hong 
Kong, being the middle child of three boys. Both of his 
parents were Eurasians of the Anglican faith. His fa-
ther, Th omas Rowan, was also born in Hong Kong but 
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died at the young age of 30. Th omas’s father was a mer-
chant captain of Scottish descent who came to Hong 
Kong in the latter half of the nineteenth century, and 
died in March 1906 at the age of 63.18 When Th omas 
Rowan passed away, Arthur’s mother, Cheui Saan Wen, 
brought the three boys back to her pre-marriage family. 
Arthur and his two brothers initially attended tradi-
tional Chinese classes and then completed their second-
ary school education at the Diocesan Boys’ School, an 
Anglican school located in Kowloon (Figure 2).
Upon his return to Hong Kong in 1927 and after a spell 
of several years as a pharmacist at the Colonial Dispen-
sary,19 Arthur became a partner and pharmacist at the 
China Dispensary in the mid-1930s. During the Japa-
nese occupation from 1942-1945 Arthur was actively 
involved in the smuggling of medicines into Stanley 
and other internment camps where British and Com-
monwealth citizens and their families were held as in-
ternees. Arthur was suspected of being a British spy by 
the Japanese military police and was arrested and beat-
en twice, resulting in permanent hearing loss to his left 
ear.
After the war, the colonial government planned to 
award a medal of bravery in recognition of Arthur’s hu-
manitarian acts in the supply of medicines to those in-
terned in Stanley and other camps, but he politely de-
clined citing Christian values and the idea that he was 
just acting as any responsible citizen would. At the end 
of the Second World War Arthur opened his own phar-
macy, Th e Willing Dispensary, located at 30-32 Des 
Voeux Road Central, Hong Kong Island (Figure 4).20
Figure 2.  Arthur Rowan in his 20s (Source: Rowan family)
After graduating from secondary school, Arthur taught 
for seven years at St. Paul’s College to save enough tu-
ition and boarding fees needed to study at Cambridge 
University in Britain. Arthur continued to pursue a 
master’s degree in chemistry at the University of Lon-
don, and then quickly changed his career track by 
passing the pharmaceutical chemist examination and 
became a registered pharmacist with the Pharmaceuti-
cal Society of Great Britain in July 1927. Among Ar-
thur’s two other brothers the elder, Th omas, became a 
lawyer and the younger, George, was a medical doctor 
(Figure 3).
Figure 3. Th e Rowan brothers; Arthur (right), Th omas 
(middle), and George (left) (Source: Rowan family)
Figure 4. Th e opening ceremony of the Willing Dispen-
sary with dragon dance in the late 1940s (Source: Rowan 
family) 
Arthur was better known by his Chinese name ‘Lau 
Chun Lun’ when dealing with customers and trading 
with local businessmen. Colleagues called him ‘Lowan’ 
(Cantonese pronunciation of the letter ‘R’ appears as ‘L’ 
sound), ‘Lau Th e Chemist’ or ‘Lau Fa’.
Lo Man Kuen, a former government pharmacist 
who is now retired, had the opportunity to work dur-
ing the summer months at Th e Willing Dispensary be-
fore he attended the pharmacy diploma course at the 
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University of Hong Kong in 1952. He remembered 
that:
Lowan’s Cough Mixture was popular in the Central 
District but it was a secret, and no one who worked 
at the dispensary knew the formula. I was responsi-
ble for boiling the syrup, and another master was 
responsible for the addition of the active ingredients 
to make the cough mixture.21
Arthur Rowan was elected as the fi rst president of the 
Hong Kong General Chamber of Pharmacy in the 
1950s.22 As a result of his eff orts, the retail pharmacy 
segment was able to implement the Antibiotic Ordi-
nance in a sympathetic manner during the Korean War, 
so that antibiotics could be sold and would be able to 
reach destinations where they were highly sought after 
for wounded soldiers with life threatening infections. 
He was also active in exchanges with other pharmacist 
groups in Southeast Asia (Figure 5).
Wong in 1936, at an age considered rather late at the 
time (Figure 6). Dorothy graduated from the Ying Wa 
(literally translated as Anglo Chinese) Girls’ School 
founded in 1900 by Helen Davies of the former Lon-
don Missionary Society. Dorothy and Rowan were 
married for 35 years until he passed away in 1971. Dor-
othy passed away at the age of 94 in 2006 in California, 
United States.
Figure 5. Arthur Rowan and visiting pharmacists from Sin-
gapore and Malaysia in the 1950s (Source: Rowan family)
In the 1950 and 1960s Rowan – at the invitation of 
Th omas Mahon, the then chief pharmacist of the colo-
nial government – was appointed as the proctor, 
charged with overseeing the biannual examinations un-
dertaken by foreign pharmacy graduates wishing to be-
come qualifi ed locally. From 1961 to 1971, as an in-
creasing number of new retail pharmacies were opened 
and the rental of retail premises in the Central District 
rose exponentially, Rowan downsized his business ac-
tivities from retail pharmacy to importing and trading 
in medicines only. His wife Dorothy subsequently sold 
off  the business soon after he died at the age of 75 in 
1971.
Rowan’s family life
Th rough the introduction of mutual Christian friends, 
Rowan, at the age of 40, married Dorothy Ying Ngan 
Figure 6. Wedding of Arthur Rowan and Dorothy Wong 
in 1936 (Source: Rowan family)
Arthur and Dorothy had four daughters; they gave 
them names with the consecutive initials G, H, I and 
J, namely Geraldine, Hermione, Imogen, and Jocelyn. 
Arthur’s wife Dorothy was a traditional wife and moth-
er. She worked as a tutor before marriage, and became 
a full-time homemaker and brought up her four daugh-
ters. Geraldine graduated from Diocesan Girls’ School 
in Jordan Road, Kowloon and the other three all fol-
lowed Dorothy’s footsteps and completed their studies 
at Ying Wa Girls’ School, an Anglican school, located 
at the junction of Robinson Road and Bonham Road, 
Hong Kong Island. When Rowan passed away in Hong 
Kong, Dorothy joined her daughters in the United 
States. Before her retirement, she worked for many 
years at senior centres in San Diego and San Francisco.
Arthur Rowan is fondly remembered by his family. 
His fourth daughter, Jocelyn, recalls:
When my father was in a good mood, he would 
crack jokes with us in Pidgin English. Over the 
weekends, he would take the entire family out to the 
Chung Chi College, the predecessor of the Chinese 
University of Hong Kong, in Shatin for fresh air and 
walk around the campus. 
He also liked swimming, and would practice free-
style in his trip to the fl oating platform and then 
used backstroke on his return trip. In his later years, 
he liked brisk walk in the mornings in a range of 2-3 
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miles as his daily exercise. Father lived on the second 
fl oor of 15 Seymour Road, Hong Kong Island before 
marriage and the family grew up there. Geraldine, 
my eldest sister, lived there until 1988 when she re-
tired from the Department of Medical and Health 
before relocating to the United States. Th e family 
had lived in the same premises for half a century. 
Jocelyn also remembered one of Arthur’s lifelong pas-
sions.
Father’s lifelong hobby was reading mystery books. 
His favourite was Sir Arthur Conan Doyle’s fi ction-
al detective Sherlock Holmes stories. When he stud-
ied in London in the 1920s, he even went to Baker 
Street and looked for number 221B. To his disap-
pointment, 221B Baker Street was non-existent 
then.23 Father could sit in his room for several hours 
reading novels which he borrowed from the libraries 
of the British and the United States Consulates. 
Once he fi nished four novels within one week, and 
the librarians were upset when they saw him coming 
back asking for more mystery books as they were not 
able to satisfy his appetite.24
Conclusion 
During the three years and eight months of Japanese oc-
cupation from 1941-1945, all western pharmacies in 
Hong Kong were closed as British pharmacists were 
locked up and Chinese pharmacists fl ed across into the 
Mainland. Th is was the lowest point of western phar-
macy since it was introduced into Hong Kong a century 
ago. Most traditional Chinese medicine shops were also 
closed since herbal medicine supply ceased due to border 
closures. Whilst no major epidemic arose, deaths due to 
starvation and other infectious diseases such as malaria 
were recorded. With closure of social hygiene clinics, ve-
nereal diseases – which were once controlled – once again 
became highly contagious as antibiotics were not avail-
able for treatment of syphilis and gonorrhea.
Arthur Rowan (aka Lau Chun Lun) was spared in-
ternment by the Japanese army who identifi ed him 
more with his Chinese rather than his Eurasian heri-
tage. He, however, risked his life and lost hearing in his 
left ear to save internees who desperately needed medi-
cines for life threatening conditions. He did this for a 
noble humanitarian cause, truly demonstrated humil-
ity, and shunned any award for his heroic eff orts. As a 
pharmacist, it was his selfl ess nature that made Arthur 
an exemplary role model in twentieth century Hong 
Kong, one who embodied many of the cornerstone vir-
tues and values that every society would be proud of 
and respect.
Author’s address: Patrick Chiu, Hong Kong Society 
for the History of Pharmacy, 1104 Crawford House, 70 
Queen’s Road, Central, Hong Kong. Email: pchiuy@
netvigator.com.
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A R T I C L E
Tribunal appeals against conscription by 
chemists and druggists in Middlesex, 
London during the First World War
Andrew Hersom
Abstract
In January 1916 the Military Service Act enabled the 
conscription of men aged between 18 and 41 years for 
military service. Certain industrial workers in ‘certifi ed 
occupations’ (which included pharmacists) were, how-
ever, initially exempted. But later that year exemptions 
were curtailed unless that person’s job was deemed essen-
tial in the national interest. Prior to obligatory conscrip-
tion, discussion between the local military representative, 
Middlesex National Insurance Committee and Mid-
dlesex Pharmaceutical Committee had agreed which 
pharmacists should be exempt from conscription. Th is 
short communication reviews 51 records of appeals 
against conscription by other pharmacists made to mili-
tary tribunals in Middlesex between 1916 and 1918.
Introduction
After two years of confl ict in the First World War us-
ing volunteers, the authorities found it necessary to in-
troduce conscription, since the numbers volunteering 
were inadequate for the needs of the military. In Janu-
ary 1916 the government persuaded Parliament to pass 
the Military Service Bill which, once enacted, enabled 
conscription of single men aged between 18 and 41 
years. Single young men were to be called up in age or-
der, but the Act exempted the medically unfi t, clergy-
men, teachers and certain classes of industrial workers 
in ‘certifi ed occupations’. In addition, conscientious ob-
jectors – men who objected to fi ghting on moral 
grounds – were also to be exempted if a tribunal found 
them to be sincere in their beliefs.
A second Act passed in May 1916 extended conscrip-
tion to married men who – like single men – were then 
called up in age order. During the last months of the war 
in 1918, the age limit was raised to 51 years. Also, early 
in 1918, any previous exemptions were cancelled.
Initially, amongst those in the long list of certifi ed 
occupations exempt from conscription were chemists, 
that is, anyone who was a ‘chemist in the sense of a per-
son dispensing medicines under the National Insurance 
Acts. 1 However, in May 1916 the list of Certifi ed Oc-
cupations was amended to:
Men lawfully and habitually engaged in dispensing 
medicines, to be exempted if agreed to be indispen-
sable for the needs of the population by the Military 
Representative, after consultation with the Insurance 
Committee for the area, or if recommended by the 
National Health Insurance Commission and ap-
proved by the Army Council.2
Th is meant that some chemists and druggists were li-
able to be called up to fi ght, unless they could justify 
otherwise.
Grounds for appealing against conscription
If a man felt he should be exempt from military service, 
he could apply to his local tribunal based at the Urban 
District Council level. If he disagreed with the local 
tribunal’s decision that he would have to join the armed 
forces, he could make an appeal to County Appeals Tri-
bunal. With permission, he could make a fi nal appeal 
to a Central Appeals Tribunal. When it came to mak-
ing an appeal, applicants could apply for an absolute, 
conditional or temporary exemption, under one or 
more of the seven ‘grounds for appeal’. Th e legislation 
(Military Service Act 1916, chapter 104) stated these as 
follows:
1. On the ground that it is expedient in the national 
interests that the man should, instead of being em-
ployed in military service, be engaged in other work 
in which he is habitually engaged;
2. On the ground that it is expedient in the national 
interests that the man should, instead of being em-
ployed in military service, be engaged in other work 
which he wishes to be engaged;
3. If he is being educated or trained for any work, on 
the ground that it is expedient in the national inter-
ests that, instead of being employed in military ser-
vice, he should continue to be so educated or 
trained;
4. On the ground that serious hardship would ensure 
if the man were called up for Army service, owing 
to his exceptional fi nancial or business obligations 
or domestic position;
5. On the ground of ill-health or infi rmity;
6. On the ground of a conscientious objection to the 
undertaking of combatant service;
7. On the ground that the principal and usual occu-
pation of the man is one of those included in the list 
of occupations certifi ed by Government Depart-
ments for exemption.
In theory, there were a great many grounds for exemp-
tion, but the government made it clear early on that 
these only applied if the exemption was ‘in the nation-
al interest’.
In this short communication the records relating to 
‘chemists’ or ‘pharmacists’ resident within the county 
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of Middlesex in London were accessed online from the 
website of Th e National Archives at Kew, London.3 Re-
cords relating to non-pharmaceutical or analytical 
chemists were excluded. A total of 51 cases were identi-
fi ed, of which 25 were identifi ed as chemists and drug-
gists or pharmaceutical chemists in the 1919 Registers 
of Pharmaceutical Chemists and Chemist and Druggists 
kept by the Pharmaceutical Society of Great Britain.4 
Th ree individuals self-identifi ed as being pharmaceuti-
cally qualifi ed, but their names do not appear in the 
1919 register. Th e remainder were identifi ed as non-
pharmaceutically qualifi ed chemist’s assistants or dis-
pensers. One appellant dispensed at Middlesex Red 
Cross Hospital. Th ere were no other hospital pharma-
cists, and incidentally, no doctors, physicians or sur-
geons listed in the appeals.
Th e appeals procedure
Individuals receiving call-up papers could either agree 
and accept, or they could claim exemption under one 
of the stated categories. Decisions about exemptions 
were initially taken at the Urban District Council level. 
Subsequent appeals were submitted to the County Mil-
itary Appeal Tribunal (the subject of this communica-
tion). Th e Military Appeal Tribunal for Middlesex was 
announced in the London Gazette on 25 February 
1916.5 It consisted of 10 members, most of whom were 
magistrates (Justices of the Peace, JP) and members of 
the Middlesex County Council (MCC). Some were, or 
would later become, chairmen of Middlesex County 
Council (Table 1).
Others were later co-opted onto the tribunal. For 
example, Charles A. Buckmaster, who was an Assistant 
Secretary on the Middlesex Education Board, also 
served. Several members had a personal investment in 
the war; Cecil Fane De Salis had four sons serving in 
the army, two of whom were killed in action. Herbert 
Nield lost one of his two sons.
In addition to the County level tribunal, local dis-
trict tribunals were constituted. Members of the Mili-
tary Appeal Tribunal for Middlesex also served on some 
of these. Th e County Appeals Tribunals had very little 
fl exibility, and many appeals were summarily rejected; 
most exemptions were conditional or temporary.
Th e County Appeal Military Representative was 
(temporary) Captain Rudolph Edward Victor Bax, of 
the Middlesex Regiment Territorial Force.6 Bax was a 
barrister-in-law before the war. Th ere were also other 
military representatives. When it came to considering 
claims for exemption from ‘men lawfully and habitu-
ally engaged in dispensing medicines’, exemption on 
the grounds of being ‘indispensable for the needs of the 
population’ was to be agreed by the Military Represen-
tative only after consultation with the Insurance Com-
mittee for the area.
Th e Middlesex National Insurance Committee7 
was chaired by William (later Sir William) Glyn-
Jones. Glyn-Jones initially qualifi ed as a pharmacist, 
and later was the Parliamentary Secretary for the 
Pharmaceutical Society of Great Britain. He had been 
instrumental in setting up the Proprietary Articles 
Trade Association (PATA) in 1896 to press for the re-
sale price maintenance of medicines, and was the key 
fi gure in persuading the government that pharmacists 
must be involved in dispensing prescriptions under 
the 1911 National Insurance Act.8 By the start of the 
war he was a Justice of the Peace, a Member of Parlia-
ment, a barrister and an Alderman of Middlesex 
County Council.
In turn, the Middlesex National Insurance Com-
mittee took advice about pharmaceutical services from 
the Middlesex Pharmaceutical Committee, chaired by 
Table 1. Members of the Middlesex Military Appeal Tribunal 1916-18
Name Status Role on MCC Other roles
Viscount Enfi eld Landowner Alderman Alderman, Hertfordshire
Henry Burt JP Member Member of Hornsey Council
Cecil Fane de Salis JP Member Landowner
James Devonshire Businessman Electrical engineer and managing director of London United 
Tramways Ltd and London and Suburban Electric Traction Co. 
Ltd.
John Dobson JP Member of Tottenham Urban District Council
Philip Hewlett Trade Unionist Great Western Railway Signalman
William Luke JP
Herbert Nield JP King’s Counsel, Member of Parliament and  Deputy Lieutenant 
for the County of Middlesex
William Regester JP Chairman
Montagu Sharpe JP Member Lawyer
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Herbert Skinner. Skinner qualifi ed as a pharmaceutical 
chemist in 1891 and lived in Highgate, north London. 
He was a member of the Council of the Pharmaceuti-
cal Society of Great Britain, and became its president 
in 1927.8
Th e secretary of the Middlesex Pharmaceutical 
Committee was Hugo Wolff , who qualifi ed as a chem-
ist and druggist in 1901. Wolff  is listed in the 1914 edi-
tion of Kelly’s Directory 9 as having a shop in South Tot-
tenham; but he was also an assistant to Alec Nathan, of 
Joseph Nathan & Co. Ltd, the company that later be-
came Glaxo.10 He was also involved with the PATA and 
resale price maintenance. After the war he became sales 
director at Glaxo.
Appeals by chemists and druggists
It is clear from the records that some members of the 
Middlesex Insurance Committee, together with some 
members of the Middlesex Pharmaceutical Committee, 
met Captain Bax, the Military Representative, to agree 
which pharmacists aged under 41 years could be ex-
empted from conscription to ensure that patients could 
continue to receive their medicines.
According to the 1914 Kelly’s Directory, there were 
279 chemist and druggist premises in Middlesex. Th is 
number is approximate as some businesses may not ap-
pear in Kelly’s Directory. It is presumed that those phar-
macists providing services deemed essential had been 
identifi ed, and those appealing were those who dis-
agreed with this assessment. Th is suggests that approx-
imately 255 pharmacies (279 less 24) were deemed es-
sential by the Middlesex Insurance Committee (and 
presumably the Middlesex Pharmaceutical Commit-
tee), and that this fi gure was agreed by the Military 
Representative.
Th e population of Middlesex in 1914 was approxi-
mately 500,000, which indicates a ratio of around 
2,000 patients per pharmacy. Th e records involving in-
dividual appeals to military tribunals (with the excep-
tion of Middlesex and Peebles and Lothian in Scotland) 
were supposed to be destroyed after the First World 
War on Government instructions due to the sensitivity 
of the cases, the Middlesex and Peebles and Lothian 
records being retained as examples.
Results of the appeals
During the 35 months between January 1916 and No-
vember 1918, a total of 51 appeals were heard by the 
Military Appeal Tribunal for Middlesex. Th ese are 
summarised in Table 2.
Table 2. Summary of Appeals heard by the Military Appeal Tribunal for Middlesex 1916-1918
Name Board
reference
Date fi rst 
appeal




F H Quadling M3 15.2.1916 26 Pharmaceutical Chemist 1911 Temporary 
exemption
G Lightfoot M16 24.2.1916 19 Chemist’s Dispenser - Appeal dismissed
F C Williams M44 16.2.1916 22 Chemist & Druggist. MPS 1915 Appeal dismissed
V C Ellis M53 17.2.1916 21 Chemist dispensing under the 
NI Act
(1) Appeal dismissed




H G Brooke M1036 20.6.1916 24 Chemist’s Dispenser - Appeal dismissed
H Blake M1165 5.6.1916 27 Pharmacist 1913 Appeal dismissed
W A Elliff M2326 E 15.9.1916 29 Pharmacist 1914 Appeal dismissed
E H Marshall M3369 20.6.1916 20 Assistant to Father (Chemist) - Withdrew appeal
B Hickox M4579 30.9.1916 21 Chemist’s Assistant - Temporary 
exemption
W Jarvis M4718 19.6.1916 33 Qualifi ed Chemist employed 
as Manager
1905 Referred to 
Oxford








H W Hall M1458 10.6.1916 32 Chemist’s Dispenser - Temporary 
exemption
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T G Matson M4403 5.9.1917 29 Chemist’s Associate - Temporary 
exemption
J R Waddell M5103 15.9.1917 34 Chemist (Dispensing) (2) Conditional 
exemption
J A Cardno M5170 26.5.1917 37 Qualifi ed Chemist & Druggist 1902 Conditional 
exemption
G Field M5641 29.6.1918 45 Chemist’s Assistant - Temporary 
exemption
C Scott M5711 7.6.1918 46 Dispensing Chemist (1) Temporary 
exemption
B W Brims M5195 12.6.1916 31 Chemist & Druggist 1907 Conditional 
exemption
K E Jordan M5328 7.1.1918 33 Pharmacist 1916 Temporary 
exemption
D O Williams V183 19.2.1916 31 Chemist’s Assistant + Dispens-
er
- Appeal dismissed
J L Mullin V594 21.3.1916 25 Chemist’s Dispenser - Appeal dismissed
J Kossick V762 31.3.1916 32 Chemist’s Assistant - Appeal dismissed
W A Fryer V1110 5.6.1916 25 Qualifi ed Pharmacist 1916 Temporary 
exemption
C B Snow V1269 18.3.1916 26 Pharmacy Owner - Appeal dismissed




F W Broadbridge V1672 16.6.1916 25 Chemist’s Assistant - Temporary 
exemption
C F Humphreys V2406 27.10.1916 - Chemist’s Assistant - Referred back
H J Heath V2570 5.5.1916 34 Stock keeper + Chemist’s 
Assistant
- Appeal dismissed
W J E Gould V2648 23.11.1916 23 Chemist (Assistant) 1915 Withdrew appeal
F E Goodfellow V2730 6.1.1916 24 Chemist 1915 Withdrew appeal
E Aspden V3156 27.12.1916 37 Chemist 1901 Appeal dismissed
A E K Moon V3333 7.2.1916 38 Chemist’s Assistant - Temporary 
exemption
CA Macdonald V3475 24.3.1917 36 Chemist & Druggist 1903 Exemption 
sustained
D S Henderson V3526 6.3.1917 24 Qualifi ed Chemist 1915 Appeal dismissed
S W Harrison V3696 14.4.1917 35 Chemist +  Optician 1906 Appeal dismissed
A A Martret V3768 13.1.1916 27 Qualifi ed Chemist, reg’d 
pharmacist
1915 Appeal dismissed
A Edmondson V4090 19.6.1917 24 Chemist’s Assistant - Appeal dismissed
J B Hewitt V4904 3.5.1918 30 Dispensing Chemist & Phar-
macist
1907 Appeal dismissed
W J H Clarke V5143 4.7.1918 33 Dispensing Chemist 1907 Appeal dismissed
J F Furnivall V2823 1.11.1916 41 Chemist & Druggist, Dentist 1901 Conditional 
exemption
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Appellant’s ages at the time of appeal varied between 
19 and 46 years of age. Th eir grounds for appealing 
against conscription also varied considerably. Tribunal 
decisions were: appeal dismissed 19, appeal withdrawn 
3, conditional exemption 6, exemption sustained 1, re-
ferred back to original tribunal 2, temporary exemption 
15 and unknown 5. Th ese are illustrated in a series of 
case studies.
Case 1: Dependent relatives
Th e fi rst case was that of Frederick Quadling of Ux-
bridge, who claimed he had tried to volunteer in August 
1914 but had been rejected on medical grounds, so he 
had bought a shop and thereby acquired signifi cant 
debt. His mother was solely dependent on him. He dis-
pensed 170 National Health Insurance prescriptions a 
month. He was given a 3 month temporary exemption, 
as the Military Representative stated that the exemp-
tion rules would soon be changing.
Quadling appealed the fi nding to the central Mid-
dlesex tribunal via his solicitor, but withdrew his appli-
cation as it was pointed out that he would get fi ve 
months exemption altogether.
Unfortunately there is no further information. 
Quadling’s name does not appear on the list of enlisted 
soldiers on the forces-records.co.uk website, but he is 
recorded in the 1919 Registers of Pharmaceutical Chem-
ists and Chemist and Druggists.4
Case 2: Indispensable to the business
Frederick Charles Williams was employed at Ernest 
Drayton in Ealing. In the dossier is a letter from the 
secretary of the Middlesex Pharmaceutical Committee, 
Hugo Wolff  MPS, confi rming that the committee was 
working with Middlesex Insurance Committee and the 
National Health Insurance Commissioners to ascertain 
what men can be spared for military service. Th e Mili-
tary Representative stated that there were two fully 
qualifi ed pharmacists in this small business, and in his 
opinion he did not consider this necessary. Also, they 
did far more dispensing for private customers than pan-
el work under the National Health Insurance Act.
Th e Ealing tribunal chairman’s reason for the deci-
sion was that Williams admitted during questioning 
that his National Health Insurance dispensing was in-
signifi cant, and that this was not his principal and usu-
al occupation. His appeal was dismissed a month later 
at the Middlesex tribunal.
Williams is not listed in the 1919 Registers of Phar-
maceutical Chemists and Chemist and Druggists, so it 
must be assumed that he did not survive military ser-
vice (there were nine soldiers with this name who died 
in the war).
Case 3: Conscientious objector
Harrold Blake appealed to the Ruislip Northwood Tri-
bunal on the basis of conscientious objection. He was 
employed at H.B. Sharman Chemists of Northwood. 
Despite writing a statement of his beliefs and two refer-
ences, the application was refused, with the recommen-
dation that he serve in a non-combatant role as a dis-
penser in the RAMC. He appealed to the Middlesex 
Tribunal and this was dismissed. Leave to appeal to the 
Central Appeals Tribunal was refused. He was called 
up, refused to serve, was court martialled and impris-
oned in Wormwood Scrubs, but he survived and re-
turned to civilian life, eventually dying in 1980.11 Har-
rold Blake is listed in the 1919 Registers of Pharmaceutical 
Chemists and Chemist and Druggists.
Case 4: Sudden death of employer
William Arthur Elliff  was employed by Alexander Mac-
kay Chemists in Hendon. He had already volunteered 
as a dispenser in the RAMC when Mackay suddenly 
A Heath V4843 15.5.1916 35 Dispensing Chemist 1909 Conditional 
Exemption
J W Butterworth V4877 3.5.1918 23 Pharmacist & Optician 1913 Appeal dismissed
B Hickox RM1/263 18.5.1918 22 Chemist’s Assistant +Dispenser - Unknown
S C Hudson RM1/1315 2.8.1918 38 Dispensing & Photographic 
Chemist
1901 Unknown
F J Mills RM1/1463 20.9.1918 26 Dispensing Chemist Assistant - Unknown
W Bridges RM1/1485 30.9.1918 32 Managing Chemist qualifi ed 1910 Unknown
M Phillips RM 
1/1460
18.9.1918 26 Chemist’s Assistant - Unknown
Notes: (1) Not listed as a pharmaceutical chemist or chemist and druggist in the Registers of Pharmaceutical Chem-
ists and Chemist and Druggists 1919. (2) Licentiate of the Pharmaceutical Society of Ireland (equivalent to a chem-
ist’s assistant) registered 26 January 1909, number 986.
Table 2. (cont.)
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died. As it was impossible to fi nd a replacement imme-
diately he therefore requested a temporary exemption 
for a few days to allow this. Th is was refused. It has not 
been possible to fi nd a record of Elliff  in the war forces 
website, but he does appear in 1919 Registers of Pharma-
ceutical Chemists and Chemist and Druggists.
Case 5: Suff ered nervous breakdown
William Jarvis was employed by W. Armitage of Eal-
ing, and he appealed to the Ealing Tribunal on the ba-
sis of his mental health (nervous breakdown). He was 
given six months’ temporary exemption. He subse-
quently moved around the country, and his exemption 
was stopped on the basis that he had stopped working 
as a pharmacist (due to his health). It is not clear what 
happened next, but he is listed in the 1919 Registers of 
Pharmaceutical Chemists and Chemist and Druggists.4
Case 6: Th e pharmacy owner
Reginald Owen Bird of John Davies Chemists, Willes-
den gave his occupation as chemists’ manager and pro-
prietor and described himself as a chemist and dentist 
(unqualifi ed). He claimed exemption on the basis he 
had been discharged from the army in 1915 and there-
after opened three ‘drug stores’. One had to be closed 
due to his inability to get someone to work there; he ran 
the other two shops with an elderly man who suff ered 
from long-term illness.
Bird challenged his medical classifi cation of B1 as 
he had congenital syphilis; this was later re-assessed at 
C1. Th e claim that he was involved in National Health 
Insurance dispensing was challenged on the basis that 
he was not pharmaceutically qualifi ed. Also, someone 
from the tribunal visited his two shops on two occa-
sions – each time the claimant was absent. Nevertheless 
he was given six weeks’ exemption on medical grounds 
and to have time to sort out his aff airs; the exemption 
was extended fi rst by four months and then for a fur-
ther six months. Bird was later imprisoned for six 
months at the Old Bailey for obtaining raw materials 
improperly by fraud.
Case 7: Heavy workload
Arthur Edmondson was employed as a dispenser at J.T. 
Davy Chemists of Fore Street, Edmonton. Th e claim 
was made by his employer, who appealed on the basis 
that dispensing 19,700 prescription items a year made 
him essential to the continuation of the panel contract 
(i.e. National Health Insurance dispensing) by the busi-
ness. Hugo Wolff , Middlesex Pharmaceutical Commit-
tee was present but did not appear to otherwise support 
the appeal, which allowed a temporary exemption of 
just a fortnight. It is possible that the view was that 
there were two other chemists in Fore Street, Edmon-
ton and that these could cope with the workload.
Conclusion
During the First World War, chemists and druggists 
were initially eligible for exemption from conscription, 
but almost immediately the government changed the 
rules, such that they would only be eligible for exemp-
tion if this was agreed by the local Military Represent-
ative and the insurance committee to be in the ‘nation-
al interest’.
Appeals presumably came from those excluded 
from these agreements, so were not representative of the 
profession as a whole. It has not been possible to locate 
any surviving records from either the Middlesex Insur-
ance Committee or the Middlesex Pharmaceutical 
Committee, and some of the tribunal records are in-
complete.
Individual dossiers make it clear that the Middlesex 
Pharmaceutical Committee had met both the Middle-
sex Insurance Committee and the local Military Rep-
resentative prior to an appeal, to agree which chemists 
were essential to sustain adequate pharmaceutical ser-
vices for the local population. Some high streets almost 
certainly had an excess of chemists. Th e Military Tri-
bunals had a very diffi  cult job, and they did their best 
according to the rules provided by the Government.12 
But, regardless of the reason given for claiming exemp-
tion, the majority of claims and appeals by chemists 
were rejected, or else the exemptions given were either 
conditional or temporary.
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Daniel Hanbury belonged to a Quaker family intri-
cately bound up with pharmacy. He qualifi ed as a phar-
maceutical chemist in 1857. He remained in business 
at Plough Court until 1870. He developed an interest 
in botanical and crude drugs. Most of his publications 
were concerned with crude drugs in common use. Phar-
macographia was his major work, for the preparation of 
which he collaborated with Professor Friedrich A. 
Flückiger at the University of Strasburg. Pharma-
cographia is a history of the principal drugs of vegetable 
origin met with in Great Britain and British India. It 
was fi rst published in 1874, and was followed by a sec-
ond edition in 1879. Daniel Hanbury was a contributor 
to the Pharmaceutical Journal and to the Journal of the 
Linnean Society. He was elected a Fellow of the Royal 
Society in 1867.
Early life and studies
Th e major sources for biographic material on Daniel 
Hanbury which became available to me are the ac-
counts by Wallis,1 Shellard,2 and Ince.3 Daniel Han-
bury was born on 11 September 1825 and was the elder 
son of Daniel Bell Hanbury and his wife Rachel.1 He 
belonged to a Quaker family intricately bound up with 
pharmacy. Daniel attended a local school in Clapham, 
south London. On leaving the school he was appren-
ticed to the family business at Plough Court, London 
and then started attending lectures at the school of 
pharmacy, recently established by the Pharmaceutical 
Society. He qualifi ed as a pharmaceutical chemist in 
1857. He remained in business at Plough Court until 
1870.
Daniel’s interest in botanical and crude drugs had 
been initiated by the lectures of Professor Todd 
Th ompson on botany and Professor Pereira on materia 
medica.2 An impressive account of his publications 
has been provided. Altogether he published 81 papers 
and by far the largest proportion of them were con-
cerned with the crude drugs then in common use. In 
order to obtain fi rst-hand information about the drugs 
and the plants which yielded them, Hanbury wrote to 
botanists, pharmacists, travellers and indeed anyone 
– including High Commissioners – who he thought 
could supply information and materials. He wrote 
many hundreds of letters and received many hundreds 
of letters in return from people living in many diff er-
ent countries around the world. He frequently sent 
money to encourage collectors to obtain fl owering 
specimens of plants.
What follows is a selective coverage of the works 
and other information pertaining to the involvement of 
Daniel Hanbury with vegetable drugs that have become 
available.
Figure 1. Portrait of Daniel Hanbury (Source: Science 
Papers, Joseph Ince (Note 3) 1876)
Pharmacographia
Pharmacographia is a monumental work, in the prepa-
ration of which Daniel Hanbury collaborated with Pro-
fessor Friedrich A. Flückiger at the University of Stras-
burg. The publication records the history of the 
principal drugs of vegetable origin met with in Great 
Britain and British India.4
Before going further a brief introduction to the life 
and career of Flückiger is helpful. Friedrich August 
Flückiger (15 May 1828-11 December 1894) was pro-
fessor of pharmacy and director of the Pharmaceutical 
Institute of the University of Strasburg.5 He studied 
chemistry and geology at Berlin University. From 1847 
to 1850 Flückiger was engaged as an apprentice in a 
pharmacy at Solothurn in Switzerland. He took his 
Apothekar degree at Strasburg, and in 1851 he moved 
to Heidelburg to continue his studies. From 1858 to 
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1866 he acted as President of the Swiss Pharmaceutical 
Society. In 1870 he was appointed professor extraordi-
nary at the University of Berne. In 1873 Flückiger ac-
cepted the appointment of professor of pharmacy at the 
Kaiser Wilhelm University of Strasburg. He held this 
chair for 20 years, in the course of which his name be-
came known and esteemed in pharmaceutical circles 
throughout the world.
In my archival collection the original Pharma-
cographia is available. It came to me from Dr C. K. Atal 
who at the time was director (1971-1984) of the Re-
gional Research Laboratory at Jammu. In the preface it 
is stated:
Th e drugs included in the present work are chiefl y 
those which are commonly kept in stores by phar-
macists, or are known in the drug and spice market 
in London. Th e work likewise contains a compara-
tively small number which belong to the Pharmaco-
poeia of India…Supplementary to these two groups 
must be placed a very few substances which possess 
little more than historical interest.
Th e volume runs to xviii + 704 pages. Th e major bulk 
of the book is occupied by a section entitled ‘Phaeno-
gamous or Flowering Plants’, largely covering ‘Dicoty-
ledons’ (pages 1-568) placed under their respective fam-
ilies; mostly the plants belong to the Ranuculaceae, 
Leguminosae, Rosaceae, Umbelliferae, Compositae, Sola-
naceae, Labiatae, Euphorbiaceae, Piperaceae, and Conif-
erae families.
Among ‘Monocotyledons’ (pages 569-664), plants 
are largely from the Zingiberacae, Melanthaceae and 
Graminae families. Next are the ‘Cryptogamous or 
Flowerless Plants’ (pages 665-682), including ‘Acro-
gens’ and ‘Th allogens’. Placed next is the ‘Index’ (pages 
685-704).
Each drug is headed by the Latin name, followed 
by such few synonyms as may suffi  ce for perfect iden-
tifi cation, together in most cases with English, French 
and German designations. Th en follow the information 
regarding the ‘Botanical Origin’, ‘History’, ‘Descrip-
tion’, ‘Microscopic Structure’, ‘Chemical Composition’, 
‘Uses’ and ‘Substitutes’.
A copy of the second edition of Pharmacographia, 
which was published in 1879, became available to me 
at the Connemara Public Library in Madras (now 
Chennai).6 I was allowed to get some selected pages 
photocopied. Th e second edition continued to be a joint 
publication. However Professor FA Flückiger noted in 
the fresh preface:
Premature death – March 24, 1875 – of my lament-
ed friend Daniel Hanbury, having deprived me of 
his invaluable assistance, I have attempted to prepare 
the new edition of our work with adherence to the 
same principles by which we were guided from the 
beginning.
Figure 2. Title page of Pharmacographia: A History of the 
Principal Drugs of Vegetable Origin met with in Great 
Britain and British India, 1874 (Source: Regional Research 
Laboratory, Jammu)
Figure 3. Friedrich August Flückiger 1828-1894 (Source: 
Chemist and Druggist 1894; 45: 880)
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In the second edition, there was a marginal increase in 
the bulk, as is apparent from the contents pages. In the 
new addition before the ‘Index’ was the ‘Appendix’ 
which covered ‘Short Biographic and Bibliographic 
Notes’ relating to authors and books quoted in the 
Pharmacographia.
Science papers
At the Connemara Public Library there also became 
available to me a copy of the publication Science Papers, 
Chiefl y Pharmacological and Botanical.7 I could get pho-
tocopies of a limited number of pages. Th e ‘Contents’, 
in addition to the ‘Memoir’ (pages 3-40) list the ‘Sci-
ence Papers’ (page 43 and onwards), ‘Addresses and 
Miscellaneous Papers’ (page 403 and onwards), and 
‘Appendix’ (page 487 and onwards). Out of these I have 
only with me a photocopy of the ‘Memoir’. Out of the 
60 illustrations, I only have a copy of the portrait of 
Daniel Hanbury.
Figure 4. Title page of the Pharmacographia: A History 
of the Principal Drugs of Vegetable Origin met with in 
Great Britain and British India; Second Edition, 1879 
(Source: Connemara Public Library, Chennai)
Epilogue
Some extracts which appeared in the obituary of Dan-
iel Hanbury in the Proceedings of the Chemical Soci-
ety may be taken note of.8 Whilst alluding to his writ-
ings we must not omit to mention the important part 
he played in the preparation of the Pharmacopoeia of 
India, a work involving much labour. He was also one 
of those deputed to draw up the Admiralty Manual of 
Scientifi c Inquiry. But botany was the science to which 
he especially devoted his attention. He contributed to 
the Transactions of the Linnean Society, and numerous 
papers by him are to be found in the Journal of the Lin-
nean Society.
Hanbury served on the juries of the International 
Exhibitions in 1862 and in 1867, and in an earlier year 
acted as Secretary to the Jury on Vegetable Products, 
the proceedings of which were conducted in French. 
Daniel Hanbury was elected as a Fellow of the Chemi-
cal Society in 1857, and as a member of its Council in 
Figure 5. Title page of Science Papers, Chiefl y Pharmaco-
logical and Botanical (Source: Connemara Public Library, 
Chennai)
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1869. In 1867, on his fi rst nomination, he was elected 
as a Fellow of the Royal Society, and as a Member of its 
Council in 1869. He was a warm supporter of the Phar-
maceutical Society of Great Britain, almost from its 
origin. He published extensively in the Pharmaceutical 
Journal; his series of papers on Chinese materia medica 
were highly regarded.
Daniel Hanbury never married, but lived with his 
parents, to whom he was a most kind and aff ectionate 
son. Th ough possessed with ample means, his habits, 
both from principle and taste, were remarkably simple 
and inexpensive. He was always an early riser. In his 
biography of Hanbury, Shellard noted:
Daniel Hanbury lived for less than 50 years, with 
only 25 years of active scientifi c life, but he is con-
sidered to have been the most outstanding British 
pharmacognosist of all, since his work gave to phar-
macy the status which it badly needed.2
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